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ABSTRACT OF DISSERTATION 
METABOLIC AND ELECTROPHYSIOLOGICAL EFFECTS OF FIBROBLAST 
GROWTH FACTOR 19 IN THE DORSAL VAGAL COMPLEX 
The dorsal vagal complex (DVC) is an important homeostatic regulatory 
center located in the hindbrain that alters vagal parasympathetic activity in 
response to central, viscerosensory, and humoral cues. Within the DVC, second-
order sensory neurons in the nucleus tractus solitarius (NTS) integrate ascending 
vagal sensory input with descending regulatory inputs from higher brain areas and 
respond to circulating hormones and glucose. In turn, the NTS projects to the 
dorsal motor nucleus of the vagus (DMV) which is comprised of cholinergic motor 
neurons and regulates gastric motility, hepatic glucose production, and pancreatic 
hormone release functions, among others.  
Fibroblast growth factor 19 (FGF19) is a protein hormone that produces 
antidiabetic effects when administered intracerebroventricularly in the forebrain. 
Lateral or third ventricle administration of FGF19 was shown to increase glucose 
tolerance, decrease body weight, and decrease food intake. However, no studies 
have been performed to understand the effects of FGF19 in the DVC. Neurons in 
the DVC express FGF receptors and regulate many of the processes that have 
been proposed to explain the antidiabetic effects of FGF19. Thus, this study was 
performed to understand both the cellular effects of FGF19 in the DVC as well as 
effects on systemic glucose regulation. 
First, the FGF19 was applied to the hindbrain to understand its effects on 
blood glucose. Fourth ventricle administration of FGF19 produced no effect on 
blood glucose concentration in control mice, but induced a significant, peripheral 
muscarinic receptor-dependent decrease in systemic hyperglycemia for up to 12 
hours in streptozotocin (STZ)-treated mice, a model of type 1 diabetes. Patch-
clamp recordings from DMV neurons in vitro revealed that FGF19 application 
altered synaptic and intrinsic membrane properties of DMV neurons, with the 
balance of FGF19 effects being significantly modified by a recent history of 
systemic hyperglycemia.  
Since the previous data indicated that FGF19 alters firing in glutamatergic 
neurons upstream from the DMV, the next study was aimed at understanding the 
electrophysiological effects of FGF19 on local glutamatergic circuits in the DVC. 
Receptor expression studies indicated that two nuclei were the most likely source 
of glutamatergic input to the DMV: The NTS and the area postrema (AP). 
Glutamate photolysis studies indicated that FGF19 does indeed increase the 
activity of glutamatergic neurons in the AP and NTS that project to the DMV. This 
effect was only seen in hyperglycemic mice. Further study indicated that FGF19 
produced mixed effects on the intrinsic excitability of NTS neurons but increased 
action-potential dependent glutamate release to the NTS in hyperglycemic mice. 
The source of this glutamate was confirmed to be the AP. 
Overall, the in vitro effect of FGF19 on DVC neuron excitability was 
complex. FGF19 produced mixed effects on the intrinsic excitability of some cells 
while substantially increasing glutamatergic transmission at multiple synapses in 
the DVC of hyperglycemic mice. In vivo, FGF19 in the hindbrain decreased blood 
glucose concentration in diabetic mice, an effect that is consistent with its observed 
in vitro effects on glutamatergic transmission. These findings identify central 
parasympathetic circuitry as a novel target for FGF19 and suggest that FGF19 
acting in the dorsal hindbrain can alter vagal output to produce its beneficial 
metabolic effects. 
KEYWORDS: autonomic, vagus nerve, diabetes, fibroblast growth factor, dorsal 
vagal complex, EPSC 
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1.1 The Dorsal Vagal Complex 
1.1.1 Overview of DVC Circuitry 
The dorsal vagal complex (DVC), located in the caudal brainstem, is the 
central hub of parasympathetic regulation of visceral homeostasis. The basic 
circuitry of the DVC can be compared to a standard reflex arc, with a sensory limb 
located in the periphery, a central limb that integrates sensory information, and an 
effector limb that projects to the periphery to regulate homeostatic processes. 
Despite the seemingly simplistic topology DVC circuitry, there are abundant points 
of modulation and specialization that allow this relatively small area of the brain to 
maintain tight, nuanced control of many disparate and vital peripheral systems. 
The first limb of this “vago-vagal” reflex is comprised of sensory neurons in 
the vagus nerve that detect several types of homeostatic signals in the viscera 
and transmit this information to neurons in the DVC, specifically, the nucleus 
tractus solitarius (NTS). The NTS integrates numerous convergent inputs, both 
neural and humoral, and subsequently projects to neurons in the dorsal motor 
nucleus of the vagus (DMV) which make up the effector limb of the reflex arc. 
Cholinergic motor neurons in the DMV then project through the descending vagus 
nerve to regulate much of the viscera. The DVC is an efficient homeostatic 
regulatory center that can produce drastic changes in the periphery in response 
to an array of signals. As such, it is paramount to understand how circuitry in the 
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DVC can be modified to alter the outcome of chronic diseases such as diabetes. 
Further detail will now be given regarding the specifics of DVC signaling. 
1.1.2 The Vago-Vagal Reflex Arc 
1.1.2.1 Ascending Input to the DVC 
The ascending limb of the DVC reflex arc is comprised of vagal sensory 
neurons with cell bodies in the bilateral nodose ganglia – found in the jugular 
foramen at the base of the skull. Vagal afferents significantly outnumber efferents, 
suggesting that the primary function of the vagus is sensory in nature [1]. Vagal 
afferents are found throughout the length of the alimentary tract with the highest 
innervation found in the esophagus, stomach, and duodenum [2]. There is further 
innervation throughout the intestines up to the left colic splenic flexure of the colon. 
These neurons are organized in a manner analogous to the dorsal root ganglion 
in that they are pseudounipolar, with distal processes in the gut containing sensory 
terminals and proximal processes that terminate centrally [3]. This allows for a 
high volume of viscerosensory information to be transmitted monosynaptically 
from gut to brain [3-6].  
Vagal afferents can be differentiated into classes based on location of the 
receptive field and the type of signal that is transduced. Muscular afferents 
innervate the smooth muscle fibers of the GI tract or in the surrounding myenteric 
ganglia and contain mechanosensitive terminals [7-9]. These neurons respond to 
muscular tension, signaling the distension and contraction of the gastrointestinal 
tract [7]. Mucosal afferents innervate the mucosal lamina propria and can contain 
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both mechano- and chemosensitive terminals. Mucosal afferents, while not 
sensitive to tension per se, respond to light deformation to the mucosa with a high 
sensitivity, likely detecting luminal particulate material [7, 10]. Chemosensitive 
mucosal afferents primarily terminate in the small intestine [11]  and are sensitive 
to chemosensory cues such as pH, nutrients, osmolarity, and temperature [10, 12, 
13] as well as circulating hormones, perhaps most notably CCK [14]. The proximal 
processes of vagal afferents terminate in the NTS in a viscerotopic manner with, 
for example, esophageal and stomach wall afferents terminating within different 
NTS subnuclei [4]. Vagal afferents communicate to the NTS primarily through 
glutamate [6].  
 
1.1.3 The NTS 
The NTS comprises the central integration leg of the canonical vago-vagal 
reflex arc. The NTS receives glutamatergic input from the aforementioned vagal 
afferent sensory neurons and integrates these signals with inputs from several 
brain areas. Afferent input to the NTS is organized viscerotopically, with sensory 
inputs from different organs terminating in different NTS subnuclei [4, 15, 16]. 
Unlike DMV neurons (discussed below), NTS neurons do not exhibit pacemaker 
activity and need to be driven by synaptic connections [17-19]. NTS neurons are 
primarily GABAergic [20-22], glutamatergic [21-23] and catecholaminergic [24, 
25]. The NTS also exhibits bidirectional communication with several other brain 
areas (for more, see Chapter 1.1.6.2). 
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1.1.4 The DMV 
The DMV makes up the last limb of the vago-vagal reflex arc and is the 
origin of parasympathetic motor supply to a large proportion of the viscera. This 
was best described via several tract-tracing studies using retrograde labelling [26-
28]. The DMV is a paired structure that lies at the ventral edge of the DVC adjacent 
to the central canal in the caudal DVC and ventral to the fourth ventricle in the 
rostral DVC. The DVC is comprised of ~20,000 neurons [12, Chapter 31] that 
innervate nearly every digestive organ, though projections to the stomach are the 
densest [29]. Most DMV neurons (>95%) are cholinergic although a small 
proportion express catecholamines and NOS [30-34]. Finally, there are a small 
population of DMV neurons that likely serve as inhibitory interneurons although 
their function is not understood [35].  
 The efferent vagus contains several branches and retrograde tracing data 
show that DMV neurons are organized mediolaterally according to which branch 
they project through [26]. The medial DMV contains neurons that project to the 
gastric vagal branches, the lateral DMV projects through the celiac vagal branches, 
and a small portion of neurons in the left DMV project to the hepatic vagal branch. 
A single organ may be innervated via multiple vagal branches. For example, the 
stomach is innervated by the gastric and hepatic branches and the duodenum is 
innervated by the gastric and celiac branches [29, 36]. 
 The activity of DMV neurons regulates numerous important visceral 
processes. The largest proportion of DMV neurons project to the stomach and 
much of the research into the functions of DMV neurons has focused here. The 
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DMV heavily regulates gastric motility through both excitatory and inhibitory 
pathways [37]. Vagal efferent outflow, likely originating in the DMV, also stimulates 
gastric secretion [38-40]. The DMV is also the primary source of vagal control over 
both endocrine and exocrine pancreatic secretions. Electrical stimulation of the 
DMV greatly increases plasma insulin concentrations and this effect was blocked 
via atropine and vagotomy, heavily suggesting a vagus-dependent mechanism 
[41]. Additionally, disinhibition of the DMV via GABAA receptor blockade in the DVC 
or inhibition of the DMV via chemogenetics modulates pancreatic endocrine and 
exocrine secretions [42-44]. 
The actions of the DMV on the liver are not fully understood. Retrograde 
labeling using a modified pseudorabies virus (PRV) indicates that there are DMV 
neurons that project to the liver [45]. However, anterograde labeling from the DVC 
shows that DMV neurons do not terminate in the hepatic parenchyma or on hepatic 
nerves or paraganglia [46]. Despite this, there is evidence that the DMV regulates 
glucose metabolism through the vagus nerve. Pocai et al. found that the 
hypothalamus controls hepatic glucose production (HGP) by exciting DMV 
neurons and that this effect was blocked via a vagotomy [47]. Moreover, injection 
of NMDA into the DVC lowers HGP, which was also blocked by a vagotomy [48]. 
DMV neurons display a diverse set of electrophysiological phenotypes. 
Most DMV neurons sustain a slow pacemaker activity (1-2 Hz action potentials) 
[49-51]. This implies that small changes in DMV excitability through modification 
of either membrane potential or synaptic input can produce dramatic differences 
in vagal motor output [52, 53]. DMV neurons receive primarily glutamatergic and 
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GABAergic inputs from the NTS, although it is thought that GABAergic control 
dominates under normal circumstances [22, 23, 25, 54]. DMV neurons also display 
electrophysiological and morphological heterogeneity depending on their target 
organ [55]. Finally, DMV neurons display heterogeneity regarding the presence of 
several voltage-gated and subthreshold potassium currents [53, 55]. 
1.1.5 The Area Postrema 
The area postrema (AP) is an important part of the DVC although it is 
traditionally not considered part of the canonical vago-vagal reflex. As a 
circumventricular organ, the AP lacks a functional blood-brain barrier and serves 
as a chemoreceptive sensory organ for the detection of humoral components [56]. 
The AP is located at the caudal end of the fourth ventricle and is located 
immediately dorsal and medial to the NTS. The AP is traditionally considered the 
primary emetic center of the brain [57]. Electrical stimulation in the AP causes 
nausea and emesis and lesions of the AP abolish nausea responses to 
intravenous poisons [58, 59].  
Recent research has highlighted the importance of the AP in metabolic 
regulation. AP neurons respond to a number of metabolic hormones including 
GLP-1, amylin, and GDF15 [60-65]. Interestingly, the AP may also participate in 
vago-vagal reflex actions. The AP receives vagal afferent input and projects 
glutamatergic outputs to the NTS and DMV [66-68]. The function of the AP to 
NTS/DMV connection is not understood. However, it seems likely that the AP may 
serve as a secondary integration center for afferent vagal input, similar to the NTS. 
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The AP also projects to more distal metabolic nuclei such as the hypothalamus 
and parabrachial nucleus [66-68]. 
1.1.6 Other Inputs to the DVC 
1.1.6.1 Actions of Hormones and Glucose in the DVC 
There is a large body of evidence suggesting that the DVC is able to sense 
blood-borne components and alter parasympathetic output accordingly. Due to 
local fenestrated capillaries, much of the DVC has access to circulating hormones 
and nutrients that might typically be excluded by the blood brain barrier [56, 69]. 
Indeed, neurons in the DVC respond to numerous humoral metabolic signals 
although in most cases it is not known what part these responses play in normal 
homeostatic regulation. 
Some neurons in the DVC are glucosensitive and different subsets of DVC 
neurons can respond with increased or decreased activity in response to a given 
change in extracellular glucose. For example, GABAergic NTS neurons respond 
with either increased (40%) or decreased (33%) excitability in response to an 
increase in ambient glucose from 2.5 to 15 mM [70]. These effects remained after 
the chemical blockade of synaptic input, indicating that these neurons directly 
sensed the changes in glucose. Furthermore, GLUT2-expressing neurons in the 
NTS sense hypoglycemia which and alter the activity of GABAergic connections 
to the DMV accordingly [71]. This produces an increase in vagus nerve activity, 
leading to a counterregulatory increase in glucagon secretion.  
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DVC neurons respond to numerous gastrointestinal hormones. For 
example, NTS and DMV neurons respond to leptin [49, 72]. Exogenous leptin 
administration to the fourth ventricle or the DVC reduces food intake for at least 24 
h and decreases food-seeking behavior [73, 74]. Leptin sensitizes neurons in the 
DVC to signals of gastric distension [75], and knockdown of leptin signaling in the 
NTS leads to hyperphagia and increased body weight and adiposity [76]. This 
suggests that leptin functions to fine-tune DVC neuronal responses to gastric 
signals during homeostatic regulation of food intake.  
The DVC also responds to insulin. Insulin produces effects on both DMV 
intrinsic excitability and on synaptic input to the DMV in a slice preparation [50, 
77]. This suggests that insulin acts on DMV neurons directly and on either AP or 
NTS neurons that are immediately afferent to the DMV. The existence of direct 
actions on the DMV by insulin is unsurprising when considering that pancreatic 
insulin secretion is under the direct control of a subpopulation of DMV neurons 
[78]. When exogenous insulin is administered to the DVC, it produces an ERK1/2-
dependent decrease in HGP. These examples are far from exhaustive, as the DVC 
also responds to glucagon [79], GLP-1 [64, 80-84], and ghrelin [85-87] among 
others. 
 
1.1.6.2 Connections between the DVC and Other Nuclei 
There is abundant evidence showing that DVC neurons make reciprocal 
connections with several other brain areas, though little is known about the 
functions of these connections. Early tract tracing studies showed that the NTS 
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projects to the hypothalamus, amygdala, parabrachial nucleus, and several motor 
nuclei including the DMV [28, 88]. Early studies also confirmed that the AP projects 
to the NTS, the parabrachial nucleus, and dorsal tegmental nucleus [67]. 
Subsequently, it was identified that the NTS receives extensive projections from 
higher brain areas including the prefrontal cortex, stria terminalis, amygdala, and 
the hypothalamus [89, 90]. The projections from other nuclei to the NTS are 
arranged so that cortical projections terminate in the dorsal NTS and subcortical 
projections terminate in the ventral NTS. The paraventricular hypothalamus also 
innervates the DMV. Finally, the hypothalamus also innervates the AP. 
Relatively little is known about the functions of the various connections 
between the DVC and other brain areas. The best studied of these is the 
descending hypothalamic to DVC connection. Evidence suggests that 
hypothalamic regulation of HGP in response to sensation of circulating nutrients 
involves a descending hypothalamus-DVC-liver circuit [47, 91]. Pocai et al. found 
that ICV infusion of a fatty acid oxidation inhibitor ST1236 decreased HGP to such 
a degree as to require exogenous glucose infusions to prevent hypoglycemia in 
rats [47]. The authors found that central blockade of fatty acid metabolism 
activated hypothalamic KATP channels, which subsequently led to an activation of 
AP, NTS, and DMV neurons as measured by c-fos expression. The effect on HGP 
was blocked via vagotomy. It was found that activation of this circuit decreased 
hepatic gluconeogenesis by decreasing liver expression of G6Pase and PEPCK, 
gluconeogenetic enzymes. A subsequent study found that the hypothalamus-
DVC-hepatic glucose production regulatory circuit requires NMDA receptor 
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activation in the DVC [92]. Together, these data indicate that the ability of the 
hypothalamus to regulate HGP in response to nutrient sensing relies on a NMDA 
receptor-dependent connection to the DVC.   
Less is known about the functions of efferent connections from the DVC to 
other brain areas but a recent example highlights the potential power that these 
connections possess. GDF15 is a member of the TGFß superfamily that is 
typically associated with anorexia and cancer cachexia [93, 94]. It has been long 
known that GDF15 potently decreases body weight through suppression of food 
intake, although only recent research identified a mechanism. In 2017, four 
independent pharmaceutical company laboratories identified GFRAL, the receptor 
for GDF15 [61-63, 95]. Intriguingly, GDF15 is expressed in the AP and to a lesser 
degree the NTS, with no expression anywhere else in the body. Administration of 
GDF15 activates GFRAL-expressing AP neurons, which then leads to activation 
of neurons in the NTS, hypothalamus, parabrachial nucleus, and amygdala [61, 
94, 96, 97]. It has been suggested that the primary mechanism of action is the 
activation of an AP to parabrachial nucleus to amygdala circuit that leads to 
conditioned taste avoidance and suppression of feeding.  Much further work is 
required understanding the connections to and from the DVC. However, the 






Diabetes is too expansive a topic to be succinctly covered here. The 
following information will be a brief overview of the disease with specifics that 
relate to the current project. Diabetes is characterized by derangements of glucose 
metabolism, leading to high glucose concentrations in the blood. Type I diabetes 
involves autoimmune destruction of pancreatic ß-cells, leading to a loss of insulin 
production and secretion [98]. Type II diabetes involves progressive insulin 
resistance, due to a combination of genetics and chronic excessive energy intake 
[99, 100].  
The brain is responsible for approximately 50% of glucose disposal while 
adipose and muscle tissue dispose of approximately 25% [101-103]. The 
remainder is disposed in the liver, red blood cells, and kidney. Diabetes decreases 
glucose clearance and induces insulin resistance in muscle tissue [104, 105]. 
However, muscular insulin resistance can only account for approximately 10% of 
the dysfunctional glucose clearance observed in diabetes [105]. This suggests 
that derangements in central metabolism are the primary cause of decreased 
glucose clearance. Diabetes causes elevated plasma glucose concentrations in 
the fasted state as well. This is likely due to decreased insulin signaling in the liver 
leading to high rates of HGP [106-109]. Since the body (usually) spends much 
more time in a post-absorptive state than in a postprandial state, it is therefore 
likely that the primary contributor to high fasting glucose levels associated with 
diabetes is the liver. 
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CNS control of blood glucose was first suggested by the physiologist 
Claude Bernard in 1854 after he observed that diabetes (as measured by 
glucosuria) could be induced by puncturing the ventral wall of the fourth ventricle 
in rabbits [110]. However, after the discovery of insulin in 1921, most study into 
metabolic regulation shifted to the periphery. Despite this, a wide body of recent 
research has highlighted that the brain contains a distributed neuronal network 
that can produce dramatic effects on glycemia when challenged with certain 
signals [for reviews, see: 111, 112-115]. Briefly, neurons primarily in the 
hypothalamus and brainstem have been shown to respond to glucose levels as 
well as numerous gut hormones. In response, these neurons regulate 
neuroendocrine hormone release, autonomic nervous system activity, and 
ingestive behavior. Current treatments for diabetes are primarily focused on 
peripheral metabolic signaling and do not take into account the important role that 
the CNS plays in metabolic regulation. Thus, research into centrally mediated 
modulation of blood glucose is paramount to develop new therapies. 
1.3 Fibroblast Growth Factors 
1.3.1 Fibroblast Growth Factor Overview 
The fibroblast growth factor (FGF) family contains a diverse group of 
signaling molecules that regulate numerous aspects of life. The field of FGF 
research began as early as 1939 when it was shown that embryo extracts were 
able to promote the growth of chicken fibroblasts, though no individual molecules 
were identified [116]. The first members of the family (FGF1 and FGF2, initially 
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known as acidic FGF and basic FGF respectively) were identified in the 1970s and 
1980s when it was discovered that bovine brain extracts were able to stimulate 
the growth of 3T3 fibroblasts [117-122]. Further members of the family were 
discovered via cell culture growth, identification of oncogenes tagged by 
retroviruses, identification of genes responsible for hereditary disease, or by 
homology-based searches of the genome [for review, see 123]. 
There are currently 23 known FGFs that differ widely according to function, 
receptor specificity, expression patterns, and secretion characteristics. FGFs are 
typically divided into three groups: canonical FGFs (further subdivided into 5 
families), intracellular FGFs (iFGF), and endocrine FGFs. The overall grouping is 
based on secretion characteristics (i.e. whether the FGF is secreted or not) and 
whether the FGF interacts with heparin sulfate (HS).  
FGFs are classified in part by their interactions with HS, a long linear chain 
of repeating sulfated disaccharides that varies in length and amount of sulfation. 
Typically, HS is found in the form of heparin sulfate proteoglycans (HSPG). 
HSPGs are complex cell surface molecules composed of heparin sulfate 
covalently linked to core proteins such as syndecan, perlecan, glypican, and agrin. 
Depending on which core protein is present, HSPGs can be cell surface 
transmembrane proteins, cell surface anchored proteins, or diffusible proteins in 
the extracellular matrix [124-129].  
HSPGs modify FGF activity in two primary ways. First, HS is a required co-
factor for the binding of all canonical FGFs to FGFRs [130-134]. Second, 
interaction with HS serves to sequester FGFs, thereby restricting their spread 
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[135]. The physical characteristics of HSPGs themselves also regulate FGF 
signaling. HS chain length and sulfation pattern regulate FGF signaling. Specific 
HS chains regulate cell-specific patterns of FGF-FGFR interaction [136-138]. 
Moreover, higher levels of HS sulfation increases FGF signaling activity [139, 140]. 
Finally, cleavage of the core HSPG protein increases FGF signaling by releasing 
FGFs that had been previously sequestered [138]. 
1.3.2 Canonical and Intracellular FGFs 
Canonical FGFs are secreted signaling molecules that act in an autocrine 
or paracrine fashion due to their high affinity for HSPGs. These FGFs are further 
divided into 5 subgroups. The FGF1 subfamily contains only FGF1 and FGF2. 
This group is defined by its lack of any classical secretory signal. Despite this lack, 
they are still translocated across the cell membrane via chaperone proteins [141, 
142]. FGF1 is notable in that it is the only FGF known to activate all FGFRs. More 
will be said regarding FGF1 later regarding its effects on metabolism. The FGF4 
subfamily is comprised of FGF4, FGF5, and FGF6. The members of this family 
contain N-terminal signal peptides that control secretion characteristics and 
activate IIIc splice variants of FGFRs 1-3 and FGFR4 [131, 132]. The FGF7 
subfamily contains FGF3, FGF7, FGF10, and FGF22. This family is defined by the 
fact that they activate the IIIb splice variant of FGFR1 and FGFR2 [131, 132]. For 
further information regarding FGFR splice variants, see Chapter 1.3.5. 
The FGF8 subfamily contains FGf8, FGF17, and FGF18. These FGFs 
contain a cleaved N-terminal signal peptide and activate IIIc splice variants of 
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FGFRs 1-3 and FGFR4 [131, 132]. The FGF19 subfamily contains FGF9, FGF16, 
and FGF20. The members of this family are notable in that they contain an internal 
hydrophobic sequence instead of a classical N-terminal signaling peptide. This 
targets members of this family for transport into the endoplasmic reticulum as well 
as for secretion from cells [143-145]. This family activates the IIIb splice variants 
of FGFR3, FGFR4, and the IIIc splice variants of FGFRs 1-3 [131, 132].  
Canonical FGFs participate in a diverse array of physiological processes 
starting from the very first stages of development. FGF4 is expressed in the 
preimplantation embryo and is required for inner cell mass proliferation [146, 147]. 
In later developmental stages, canonical FGF signaling is key in regulating 
organogenesis and limb development [148-150]. Canonical FGFs, primarily FGF8, 
are also vital for nervous system development. FGF8 signals the anterior to 
posterior structuring of the telencephalon [151]. Canonical FGF signaling also 
regulates myelination, and FGF22 and FGF7 are required for the synaptogenesis 
of excitatory and inhibitory synapses respectively [152-154].  
Intracellular FGFs (knowns as iFGFs) are notable in that they are not 
secreted and do not interact with FGFRs [155]. The iFGF family is comprised of 
FGF11, FGF12, FGF13, and FGF14. iFGFs interact with voltage-gated sodium 
channels (Nav). The iFGFs serve to regulate the localization of Nav channels, 
helping to concentrate them at the axon hillock and axon initial segment. 
Moreover, iFGFs regulate the gating properties of Nav channels in numerous cell 
types including neurons and cardiomyocytes [156-160]. 
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1.3.3 Endocrine FGFs 
The final group of FGFs is the endocrine FGFs, comprised of FGF 15/19, 
FGF 21, and FGF23. FGF15 and FGF19 are considered to be orthologs in mice 
and humans respectively and can be thought to serve the same function. For more 
information, see the section on FGF19. Endocrine FGFs are secreted, similar to 
the canonical group, yet there exists an important distinction in that endocrine 
FGFs interact weakly with HS. This allows members of this group to freely diffuse 
away from their tissues of origin and act as endocrine hormones [161].  
Instead of HS, endocrine FGFs require the presence of members of the 
klotho family as co-receptors to activate FGFRs [162]. FGF15/19 and FGF21 
signals using ß-klotho while FGF23 signals using α-klotho [163-167]. Importantly, 
klotho distribution is a vital determinant of endocrine FGF tissue specificity. This 
is because, although FGFRs are heavily distributed throughout the body, klotho 
distribution is much more restricted [168]. FGF23 primarily functions in phosphate 
metabolism and thus is of little importance here. However, FGF15/19 and FGF21 
produce remarkable effects on metabolism throughout the body. These two 
members of the family, along with FGF1, will be discussed in the following section 




1.3.4 FGFs and metabolic regulation 
There is an enormous body of research over the past 80 years regarding 
the functions of FGFs that was only briefly addressed above. However, it was only 
relatively recently discovered (~20 years) that FGF signaling is important in the 
regulation of energy metabolism. The FGFs outlined within this group have all 
been linked to the actions of nuclear receptors that are well known to modulate 
metabolism. FGF1 is involved in adipose signaling and is regulated by PPARγ, a 
lipid sensor [169]. FGF15/19 is involved in cholesterol and bile metabolism and is 
regulated by the bile acid sensor FXR [170]. Finally, FGF21 is involved in the 
fasting response and is targeted by PPARα, a fatty acid sensor [171]. 
 
1.3.4.1 FGF19 
1.3.4.1.1 FGF19 Overview 
FGF15 and 19 are considered to be orthologs in the mouse and human 
respectively. Most FGFs are heavily conserved between mice and humans, 
showing a 90% or greater agreement in amino acid sequence yet FGF15 and 
FGF19 only show ~43% agreement [172] between species. Despite this, FGF15 
and 19 show similar expression patterns [168, 172] and produce similar effects on 
metabolism and gene expression in mice [170, 173]. Because FGF19 is more 
stable than FGF15 and produces the same beneficial metabolic effects even when 
administered to mice, most research in this area has focused exclusively on 
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FGF19. Thus, the remainder of this section will discuss FGF19 unless specifically 
noted. 
FGF19 was first identified using a PCR/cDNA-based screen for novel FGFs 
in human fetal brain tissue [172]. FGF15 has been shown to participate in the 
organization of the CNS by promoting differentiation of neural precursors [174, 
175], thus it is likely that FGF19 performs similar functions in humans. After 
development, FGF15 is no longer expressed in the CNS [168] and is thereafter 
primarily involved in the regulation of bile acid metabolism. 
Bile acids are small amphipathic detergent molecules that serve to break 
up lipid droplets and solubilize them for absorption [176]. Bile acids are produced 
in the liver released from the gall bladder into the small intestine after a meal. They 
travel to the distal small intestine (the ileum) where they are reabsorbed and 
transported back to the liver via the portal vein. Because bile acids are toxic to 
cells, their synthesis and release must be tightly regulated. This is accomplished 
by altering the transcription of several proteins found in the bile acid synthesis 
pathway.  
A primary determinant of bile acid synthesis is the cholesterol 7α-
hydroxylase enzyme (CYP7A1). It was suggested well before the discovery of 
FGF19 that there must be some secreted factor that regulates bile acid synthesis 
since intestinal administration of bile acids suppresses CYP7A1 expression [177]. 
Subsequent research found that specific bile acids (cholic acid and 
chenodeoxycholic acid) in the ileum stimulate the farnesoid X receptor (FXR), a 
member of the nuclear receptor family [178].  
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Since FXR agonists were shown to induce FGF19 release from human 
hepatocytes, it was suggested that FGF15/19 could be the missing secreted factor 
[179]. Further studies confirmed this hypothesis by showing that FXR was unable 
to repress CYP7A1 activity in FGF15-KO mice [170].  Additionally, administration 
or sequestration of bile acids in humans has been shown to increase or decrease 
circulating FGF19 in humans respectively, suggesting that the pathway is 
conserved between species. Bile acid stimulation of FXR causes FGF19 to be 
released from the ileum into the portal vein, where it travels back to the liver. 
FGFR4 and ß-klotho knockout mice show increased CYP7A1 expression and fail 
to reduce bile acid synthesis in response to exogenous FGF15/19 [170, 180-182]. 
Thus, FGF15/19 interacts with hepatic FGFR4 to decrease bile acid synthesis. 
Shortly after the discovery of FGF19, pioneering work from the 
pharmaceutical company Genentech identified several beneficial metabolic 
effects caused by systemic FGF19. Transgenic overexpression of FGF19 was 
found to decrease body weight and adiposity despite increasing food intake [183]. 
These mice also failed to become obese or hyperglycemic when maintained on a 
high-fat diet (HFD). This was explained via multiple mechanisms. First, it was 
found that the transgenic FGF19 mice displayed increased metabolic rate without 
any change in activity. Interestingly, there was no difference in fasted metabolic 
rate between the groups, suggesting that the FGF19-induced increase in 
metabolism was reliant on energy availability. Second, FGF19 increased the mass 
of brown adipose tissue (BAT) depots in these mice.  Mice with genetically induced 
reductions in BAT mass become obese and hyperphagic [184]. Furthermore, 
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FGF19 increased fourfold the uncoupling protein UCP-2 in BAT depots in these 
mice. UCP-2 is inversely correlated with body fat in humans [185].  
Similar work from within the same laboratory showed that recombinant 
FGF19 produced many of the same effects. In mice fed a HFD, exogenous FGF19 
increased metabolic rate and prevented weight gain with no effects on food intake 
[186]. Additionally, FGF19 treatment prevented or reversed diabetes in mouse 
models with genetic ablation of BAT or with leptin (ob/ob mice). This study found 
that FGF19 also increased liver expression of the leptin receptor and decreased 
hepatic acetyl coenzyme A carboxylase 2, leading to increased fatty acid 
oxidation. However, the most interesting result from this study was the finding that 
FGF19 alters metabolism when administered centrally. FGF19 injected into the 
lateral ventricle increased metabolic rate. This is unlikely to be due to spillover into 
the periphery since a small dose (0.5 µg) given centrally produced an effect on 
metabolic rate while the same dose given peripherally did not.  
The initial studies outlined above were the first to identify FGF19 as a 
metabolically active hormone but failed to establish a mechanism for these effects. 
There has been much subsequent research subsequent identifying the effects of 
FGF19 throughout several metabolically important tissues. It appears that FGF19 
(as well as the other two metabolic FGFs) primarily signal in the liver, adipose 




1.3.4.1.2 FGF19 Actions in the Liver 
In light of FGF19’s established effects on the liver via FGFR4, initial 
research focused on this system. FGF15 and FGFR4 knockout mice became 
hyperglycemic and showed increased rates of gluconeogenesis [173]. Similarly, 
another study found that FGFR4 knockout caused hyperlipidemia, glucose 
intolerance, and insulin resistance [187]. Interestingly, this same study found 
through re-expressing FGFR4 in the livers of FGFR4-KO mice, that hepatic 
FGFR4 was required for whole-body lipid metabolism but dispensable for glucose 
metabolism.  
Subsequent studies found that FGF19 affects hepatic glucose metabolism 
by causing hepatic protein and glycogen synthesis similar to the effects of insulin 
on the liver [188]. While insulin requires the Akt-mTOR intracellular cascade to 
achieve this effect, FGF19 was found to work through an ERK-RSk signaling 
pathway. Since diabetic insulin resistance occurs primarily upstream of Akt, this 
indicates that FGF19 may be able to circumvent some of the dysregulated 
pathways seen in type II diabetes [189]. One additional important discovery 
regarding the actions of FGF19 in the liver is that FGF19 has mitogenic properties. 
By activating FGFR4, FGF19 can cause the proliferation of hepatocytes and can 
induce hepatocellular carcinomas [190]. To combat this, specific FGF variants 
have been created that retain their beneficial metabolic effects without activating 
FGFR4 [191, 192]. 
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1.3.4.1.3 FGF19 Actions in Adipose Tissue 
 FGF19 signals primarily through FGFR1 and FGFR4 [193]. Multiple studies 
have shown that FGF19 interacts with FGFR1, not FGFR4 to improve glucose 
metabolism [194, 195]. Since FGFR1 is only sporadically expressed in the liver, it 
was hypothesized that FGF19 may alter metabolism via interactions with other 
tissues [168]. One potential target is adipose tissue since both white adipose tissue 
(WAT) and BAT express high levels of FGFR1 and ß-klotho. However, WAT-
specific knockout of FGFR1 does not prevent FGF19’s beneficial effects on blood 
glucose. Moreover, genetic ablation of ß-klotho in adipose tissue does not block 
the effects of FGF19 [196]. Given the aforementioned increases in BAT mass, it is 
likely that FGF19 does alter adipose signaling. However, it does not seem to alter 
glucose regulation through this tissue. 
1.3.4.1.4 FGF19 Actions in the Brain 
Recent research has suggested that the brain is the primary target for 
FGF19’s beneficial metabolic effects. Lan et al. showed that ablation of ß-klotho 
in the brain blocked the effect of FGF19 on weight loss whereas ablation of ß-
klotho in either adipose tissue or hepatocytes did not. As mentioned previously, 
early research established that low dose FGF19 increased metabolic rate when 
injected into the lateral ventricles [186]. These findings inspired four key studies 
as well as those included in Chapter 3 of this work. The overall message of the 
combined research in this area is clear: FGF19 injection into the brain produces 
potent antidiabetic effects. However, there are several differences between the 
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studies regarding mechanisms and techniques. Each study was performed by a 
different research group and no groups performed more detailed follow-up studies. 
As such, there remains a lack of consensus regarding the effects of FGF19 in the 
brain and a somewhat shallow understanding of each individual effect. 
The first detailed study on FGF19 in the brain came from the Seeley lab 
and established several interesting effects [197]. This study was performed in lean 
and high-fat diet fed rats. Firstly, it was shown that HFD was able to reduce the 
expression of FGFR1 and FGFR4 in the hypothalamus. This suggested that 
intracerebroventricular (ICV) FGF19 would not be as effective at regulating 
metabolism in these mice, although this was not the case. ICV FGF19 was able 
to reduce 24 hr food intake and body weight in both chow-fed and HFD mice in 
approximately equal amounts. The researchers further established that ICV 
FGF19 significantly improves glucose tolerance in an insulin-independent manner. 
Interestingly, this study also showed that CNS regulation of metabolism also 
involves endogenous FGFR signaling since the ICV administration of an FGFR 
antagonist increased food intake and decreased glucose tolerance. While these 
results were promising, they failed to establish any mechanistic details 
The second key study in this area came from the Schwartz group and was 
the first to propose a mechanism for ICV FGF19’s beneficial effects on blood 
glucose regulation [198]. These studies were performed in leptin-deficient ob/ob 
mice. First, researchers established the ability of FGF19 to decrease fasting blood 
glucose and glucose tolerance in these mice in an insulin-independent manner. 
To understand the contribution of CNS FGFR signaling to the systemic FGF19-
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induced antidiabetic effects, FGF19 was administered intraperitoneally with 
concurrent ICV FGFR antagonist administration. It was found that FGF19’s 
actions in the CNS account for approximately 50% of its total systemic actions on 
blood glucose. To understand how FGF19 was able to improve glucose tolerance, 
the authors used a frequently sampled i.v. glucose tolerance test (FSIGT) 
combined with the minimal model analysis. This methodology allows for 
quantitative measures of, among others, insulin secretion, insulin sensitivity, and 
glucose effectiveness (GE) [199, 200]. GE is the body’s ability to dispose of 
glucose independently of insulin and GE is impaired in humans and mice with 
diabetes [199, 201]. The authors found that FGF19 was able to improve glucose 
homeostasis by increasing GE, with no effects on insulin secretion or sensitivity. 
This was hypothesized to occur via increased metabolism of glucose to lactate, 
possibly through changes in liver enzyme expression. Finally, the authors showed 
that ICV FGF19 does not activate hypothalamic POMC neurons and still reduces 
blood glucose in melanocortin-4 receptor-KO mice, suggesting that ICV FGF19 
does not work through the melanocortin system. 
The third study in this area was the first to establish a CNS mechanism for 
the central delivery of FGF19 [202]. These studies were performed in HFD and 
leptin-deficient (ob/ob) mice. Firstly, the authors showed that systemic delivery of 
FGF19 was able to stimulate ERK signaling in AGRP/NPY but not POMC neurons 
in the hypothalamus. Phosphorylated extracellular signal-related kinase (pERK) is 
often used as a hallmark for FGFR activation. Using c-Fos staining, the authors 
further established that FGF19 inhibited AGRP/NPY neurons. Importantly, the 
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authors showed that the FGF19-mediated improvements in blood glucose are 
reliant upon ERK signaling since ICV administration of an ERK inhibitor blocked 
these effects. Thus, these data identified a central mechanism: FGF19 inhibits 
AGRP/NPY neurons in the hypothalamus by activating intracellular pERK 
signaling. 
The fourth and final study on FGF19 in the brain is unique in both 
methodology and animal model used [203]. First, the authors of this study chose 
to use a type I diabetic (T1DM) rat model. All prior research in this area had been 
performed in WT rodents or models of diet-induced obesity (DIO) or leptin 
deficiency (ob/ob). However, all previous findings pointed towards an insulin-
independent mechanism, suggesting that ICV FGF19 would also work in a T1DM 
model. The methodology used here also differed from others in that the authors 
measured HGP, whole-body glycolysis, and whole-body glycerol and palmitate 
turnover. This was measured by injection of radioactive glucose, glycerol, and 
palmitate with subsequent analysis via scintillation counter and gas 
chromatography. The authors found that ICV FGF19 lowered blood 
concentrations of glucose, corticosterone, ACTH, fatty acids, and glycerol with no 
changes to adrenergic hormones, glucagon, or insulin. The authors then found 
that ICV FGF19 decreased HGP, whole body palmitate turnover, and whole-body 
glycerol turnover. Importantly all effects of FGF19 were reversible by co-
administration of corticosterone. The authors concluded that ICV FGF19 
suppressed the hypothalamic-pituitary-adrenal axis, thereby reducing blood 
glucose concentrations. Moreover, this paper established that not only does ICV 
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FGF19 not alter insulin secretion, but that it also does not require intact insulin 
signaling to produce its effects. 
1.3.4.1.5 FGF19 and Bariatric Surgery 
There is a growing body of research linking FGF19 to the antidiabetic 
effects of bariatric surgery procedures [204]. Bariatric surgery procedures such as 
the Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) 
provide long-term improvements to blood glucose concentration in addition to 
body weight. Bariatric surgery involves either reduction of the size of the stomach 
(VSG) or stomach reduction with the additional rerouting of the small intestine 
(RYGB).  Although initial theories held that the primary benefits of these surgical 
procedures were the result of a smaller stomach, there is evidence that this is not 
the case. A large proportion of patients with diabetes can cease taking their 
diabetic medications within several days of receiving surgery [205]. This effect was 
not replicated in patients that lost weight and improved glycemic control via 
traditional medical therapy. This suggests that there must be a distinct underlying 
mechanism that is induced by surgical means that is absent from other treatments. 
Bariatric surgery causes numerous changes in gut physiology but one of 
the most promising involves bile acid regulation. In both humans and rodent 
models, bariatric surgery alters the levels and composition of bile acids [206-209]. 
The changes in bile acid regulation seen in bariatric surgery are not observed in 
patients on a hypocaloric diet that produced similar amounts of weight loss [210]. 
Moreover, studies have shown that bile acid supplementation can produce a host 
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of beneficial metabolic effects including increased metabolic rate, increased BAT 
activity, decreased appetite, and improved glucose metabolism [211-214]. 
Interestingly, surgical diversion of bile acids into the ileum of DIO rodents 
recapitulates the effects of RYGB on body weight, fat loss, and carbohydrate 
metabolism [215, 216].  
One likely explanation for these effects involves FXR and FGF19. Unbiased 
pathway analysis revealed that VSG regulates FXR, which is perhaps unsurprising 
considering the effects of VSG on bile acid dynamics [217]. However, the same 
study showed that the effects of VSG were blocked in FXR knockout mice. While 
VSG decreased food intake, body weight, and blood glucose concentrations in WT 
mice compared to sham counterparts, FXR-KO mice showed no difference in body 
weight and increased food intake and blood glucose concentration compared to 
their counterparts.  
Bariatric surgery rapidly increases circulating FGF19 in both rodents and 
humans [218, 219]. Moreover, post-VSG/RYGB bile acid and FGF19 levels are 
predictive of improvements in diabetic outcomes [220]. Finally, VSG performed in 
FGF15 knockout mice reduces body weight but fails to improve blood glucose 
[221]. However, the authors of this study are careful to point out that there are 
caveats regarding the differences between FGF15 and FGF19. In contrast to 
FGF19, high circulating levels of FGF15 do not correspond to improvements in 
blood glucose or pancreatic ß-cell mass [222]. These caveats are not particularly 
detrimental to the theory, although clinical trials in humans are needed. Together, 
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these data suggest that bariatric surgery improves blood glucose by increasing 
circulating FGF19 secondary to an increase in bile acid secretion.  
 
1.3.4.2 FGF21 
FGF21, another member of the endocrine FGFs, shares a number of 
similarities with FGF19 regarding metabolic effects and receptor activity. However, 
there are several important differences as well. FGF21 was first discovered during 
a screen for new FGFs in a mouse embryo cDNA library [223]. Kharitonenkov et 
al. then showed that FGF21-transgenic mice were resistant to diet-induced obesity 
and exogenous FGF21 lowered plasma glucose and triglycerides in ob/ob and 
db/db mice [224]. Subsequent studies found that FGF21 was effective at lowering 
body weight, blood glucose, insulin, and triglycerides as well as improving 
LDL/HDL cholesterol balance in rodent and primate metabolic models [224-227]. 
FGF21 profoundly increases insulin sensitivity. Acute injection of FGF21 
decreases blood glucose and increases insulin sensitivity in ob/ob mice and DIO 
mice [228]. Moreover, chronic FGF21 (3-6 weeks) lowers HGP and improves 
insulin-stimulated glucose uptake in several tissues [229]. It is likely that FGF21 
acts in roughly the same target tissues as FGF19, since FGF19 and FGF21 
require the presence of ß-klotho and have similar FGFR affinities [131]. Consistent 
with this, FGF21 stimulates ERK phosphorylation in the liver, WAT, and BAT [164, 
230]. Moreover, ICV FGF21 into DIO rats increases insulin sensitivity by 
increasing insulin-induced suppression of HGP [231]. Although the antidiabetic 
effects of ICV FGF21 are broadly similar to FGF19, ICV FGF21 also increased 
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food intake. This suggests that even the small differences in FGFR affinities 
between FGF19 and FGF21 are sufficient to cause opposite effects.  
Interestingly, the physiological actions of FGF21 run somewhat contrary to 
those observed with pharmacological doses. FGF21 is released during prolonged 
fasting and regulated by PPARα, a nuclear fatty acid sensor [171]. PPARα is a 
crucial component of the starvation response. PPARα-KO mice show impaired 
hepatic fatty acid metabolism but this phenotype can be partially rescued with 
exogenous FGF21 [171]. FGF21 is also heavily induced by a low carbohydrate, 
high fat “ketogenic” diet [232]. Additionally, transgenic mice with consitutively 
increased FGF21 show increased hepatic gluconeogenesis, fatty acid 
metabolism, and ketogenesis [229].  
FGF21 also contributes to both increases and decreases of body 
temperature, depending on the circumstance. FGF21 is implicated in the mouse 
torpor response. Torpor is a phenomenon where starvation leads to decreased 
physical activity and body temperature in an attempt to conserve energy [233]. 
FGF21 transgenic mice display an increase in extrapancreatic lipases – a sign of 
torpor [234]. 24-h fasted FGF21 transgenic mice present with a 10°C drop in body 
temperature along with a substantial decrease in physical activity [171]. FGF21 is 
also part of the cold adaptation response. Cold ambient temperature induces 
FGF21 in BAT [235, 236]. Exogenous FGF21 stimulates the expression of UCP-
1 and deiodinase-2 (thermogenic genes) in BAT and UCP-1 in WAT [226, 237]. It 
is not entirely known how FGF21 contributes to both increases and decreases in 
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body temperature but it is hypothesized that the differences in effects can be 
explained by target tissue and energy balance state. 
 
1.3.4.3 FGF1 
Although FGF1 is not considered an endocrine FGF, it produces some of 
the most potent and lasting metabolic effects known of any molecule. FGF1 is 
produced in many tissues but is found primarily in the brain, kidney, heart, and 
lung [168]. Within the CNS, the highest expression of FGF1 is found in the spinal 
cord and brain stem although most areas surveyed showed at least moderate 
expression. FGF1 is well known to participate in would healing, neurogenesis, 
angiogenesis, and development. Despite this, FGF1 knockout mice are viable and 
do not display an apparent deficiency in these processes [238, 239]. However, 
FGF1 seems to be involved in the response to aberrant energy intake, since 
FGF1-KO mice show pronounced hyperglycemia and insulin resistance when fed 
a HFD [191].  
FGF1 was the first FGF that was demonstrated to be involved in central 
regulation of food intake. Ependymal cells lining the third ventricle were shown to 
release FGF1 (then known as acidic FGF or aFGF) in response to an increase in 
circulating glucose after feeding [240]. The authors then found that ICV FGF1 
dose-dependently suppressed food intake. As discussed previously in Chapter 
1.3.2, FGF1 is a member of the canonical FGF family. As such, in physiological 
situations, FGF1 acts in an autocrine or paracrine manner due to HSPG binding. 
When FGF1 is secreted from ependymal cells, FGF1 acts locally within the lining 
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of the third ventricle to excite tanycytes and hypothalamic astrocytes [240-243]. 
When FGF1 is administered to the third ventricle, feeding suppression is sustained 
for 24 h but is greatest within 2-6h [242-244]. Interestingly, internalized radioactive 
FGF1 is observed in neurons at 18 h, not 5 h, after ICV administration [245]. This 
suggests that the stronger initial phase of FGF1-mediates food intake suppression 
is mediated through actions in astrocytes where the later phase may be mediated 
by direct actions on neurons. 
The glucose-lowering effect of FGF1 was only recently discovered but has 
garnered attention due to the magnitude and duration of effects. A single ICV 
injection of FGF1 was significant to normalize blood glucose for at least 17 weeks 
in ob/ob mice [246]. The authors of this study further tested this paradigm in db/db 
and DIO + low dose streptozotocin mice as well as Zucker diabetic fatty (ZDF) rats 
and found similar results. Similar to previous studies, the authors found that ICV 
FGF1 activated hypothalamic tanycytes. The peripheral mechanism for this action 
is not completely understood but appears to involve several tissues. The authors 
found that ICV FGF1 increased glucose clearance rate and basal circulating 
lactate. This implies an increase in metabolism of glucose to lactate similar to the 
mechanism proposed for FGF19. However, the authors also found an increase in 
hepatic glycogen content, implying increased rates of glycogen storage. Finally, 
the authors found that skeletal muscle glucose clearance was increased.  
 The findings above inspired a string of subsequent studies by the same 
research group aimed at identifying the effects of ICV FGF19. First, pERK staining 
was performed after ICV FGF1. This identified the hypothalamic arcuate nucleus-
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median eminence as a prime target [247]. Direct parenchymal injections of low 
dose FGF1 were sufficient to cause >3 week remission of hyperglycemia whereas 
the same dose injected into other hypothalamic nuclei failed to produce an effect. 
In another study, the authors identify multiple key details about the peripheral 
response [248]. The authors show that ICV FGF1 delays the onset of ß-cell 
dysfunction in ZDF rats and increases hepatic glucose uptake through a twofold 
increase in liver glucokinase activity.  
The next study from this group showed that perineuronal nets are necessary 
for the effect of ICV FGF1 [249]. Perineuronal nets are an extracellular matrix 
subtype that surrounds certain neurons and greatly influences their excitability. 
The authors show that enzymatic digestion of the perineuronal nets surrounding 
the arcuate median eminence shortens the duration of the antidiabetic effect of 
ICV FGF1. In the most recent paper, the research group identifies the cell types 
affected by ICV FGF1 via single cell transcriptomic analysis [250]. As previously 
suggested, these findings showed that ICV FGF1 preferentially activated non-
neuronal populations with tanycytes and ependymal cells dominating the early 
response and oligodendrocytes dominating the later response. Together, these 
data suggest that ICV produces a potent and long lasting response through several 
central and peripheral mechanisms. The duration and potency of the effects 
indicate that central FGF1 signaling may be a promising and potentially paradigm-
shifting drug development candidate. 
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1.3.5 FGF Receptors 
There is an enormous body of research identifying FGFRs and their 
functions. What follows will serve as a brief survey of FGFR discovery and 
function. FGFR1 was first discovered by crosslinking a radioactive variant of FGF2 
in fractions of chicken embryo membrane [251]. The receptor was sequenced 
using a trypsin degradation and subsequent matching to a cDNA library. FGFRs 
2-4 were discovered using homology based cloning against FGFR1[252-256]. 
FGFRs 1-3 also display two alternative splicing variants (termed IIIb and IIIc) that 
greatly affect ligand binding affinities [257-261]. Thus, there are seven total 
FGFRs. The actions of FGFs are dictated in part by their receptor affinities and 
FGF1 is the only known FGF that activates all FGFR subtypes [131]. FGFR splice 
variation is a key regulator of organogenesis and limb formation. For example, 
mesenchymal tissue expresses IIIc variants of FGFR1 and FGFR2 which are most 
often activated by epithelial-derived FGFs [262, 263]. Conversely, epithelial 
tissues express IIIb FGFR splice variants, which are most often activated by 
mesenchymal-derived FGFs [264, 265]. This reciprocal signaling pattern is 
important for the spatial patterning of structures such as the lung, limb buds, and 
skin.  
FGFRs are tyrosine kinase receptors and, as such, signal through receptor 
dimerization, leading to trans/autophosphorylation of tyrosine residues [266]. 
Once the receptor dimer is activated, it recruits four major intracellular signaling 
pathways by phosphorylating certain adaptor proteins. The major signaling 
pathways are: RAS-MAPK, PI3K-AKT, PLCγ, and STAT (1,3,5). Activation of the 
34 
 
RAS-MAPK pathway by FGFRs leads to induction of the MAP kinases ERK1/2. 
JNK, and p38 [267-271]. As noted elsewhere in this document, measurement 
ERK1/2/ phosphorylation is the primary method by which researchers confirm 
FGFR engagement. FGFR activation of the PI3K-Akt pathway leads to inactivation 
of FOXO1 and activation of mTOR complex 1. Both of which serve pro-
survival/proliferation, anti-apoptotic functions [272]. FGFR phosphorylation of 
PLCγ hydrolyzes PIP2, leading to IP3 and DAG. This leads to increased 
intracellular calcium release and activation of protein kinase C. Finally, FGFR 
phosphorylation of STAT (1,3,5) leads to the activation of many target genes which 




2 Materials and Methods Summary 
2.1 Animals 
Adult (3-12) week old male and female GIN mice (FVB-Tg (GadGFP) 
4570Swn/J; Jackson Laboratory) were used for all experiments. These mice 
express GFP in somatostatin-expressing GABA neurons, which allows for easier 
targeting of specific subpopulations of neurons. This property was of no use for 
the experiments in Chapter 3, as the neurons targeted (DMV) are cholinergic. 
However, it was expected that further experiments were to be performed in the 
NTS (Chapter 4) and using the same mouse model throughout the project allows 
for better comparability of results. Using this model is crucial for targeting 
glutamatergic NTS neurons. Most experiments were performed in both 
normoglycemic and hyperglycemic mice.  Hyperglycemic mice were produced 
using streptozotocin (STZ) to produce a model of Type 1 diabetes (T1DM). All 
procedures and experiments were approved by the University of Kentucky 
Institutional Animal Care and Use Committee. 
2.2 Brain Slice Preparation 
Mice were anesthetized with isoflurane inhalation to effect (i.e. lack of foot 
pinch response) and decapitated. The brain was rapidly removed and submerged 
in ice-cold, oxygenated (2-4°C; 95% O2/5% CO2) artificial cerebrospinal fluid 
(ACSF) composed of (in mM): 124 NaCl, 3 KCl, 26 NaHCO3, 1.4 NaH2PO4, 11 
glucose, 1.3 CaCl2, and 1.3 MgCl2. The hindbrain was mounted to a sectioning 
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stage and coronal brainstem slices (300 µm) were cut using a vibratome (Series 
1000; Technical Products International, St. Louis, MO). Slices were transferred to 
a holding chamber and incubated for 1 hour in warmed (30-33°C), oxygenated 
ACSF. For experiments, a single slice was transferred to the recording chamber 
on a fixed-stage, upright microscope (BX51WI; Olympus, Melville, NY) and 
continuously superfused with warmed (30-33°C) ACSF, identical to the slicing 
ACSF except when drugs were added, as described.   
2.3 Electrophysiological Recordings 
Whole-cell, patch-clamp recordings were performed under visual control 
using infrared illumination and differential interference contrast (i.e., IR-DIC) 
optics. Glass recording pipettes (1.65 mm OD, 1.2 mm ID; King Precision Glass, 
Claremont, CA) were filled with a solution containing (in mM): 130 K-gluconate (or 
Cs-gluconate), 1 NaCl, 5 EGTA, 10 HEPES, 1 MgCl2, 1 CaCl2, 3 KOH, 2 Mg-ATP; 
pH=7.2–7.3, adjusted with 5M KOH (or CsOH).  In some experiments, Cs+ was 
used as the primary cation charge carrier in the recording pipette, which prevents 
K+ current-dependent drug effects. Open tip resistance was 3-5 MΩ; seal 
resistance was 1-7 GΩ. For cell-attached recordings, pipettes were filled with 150 
mM NaCl. Neuronal activity was recorded using a Multiclamp 700B amplifier, 
Digidata 1440A digitizer, and pClamp 10.6 software (Molecular Devices, Axon 




2.4 Drugs Used for Electrophysiology Experiments 
All drugs used for electrophysiology experiments and their respective 
concentrations were: Fibroblast growth factor 19 (FGF19; 230 pM; ProspecBio, 
Ness Ziona, Israel), tetrodotoxin (TTX; 2 µM; Alomone Labs, Jerusalem, Israel), 
kynurenic acid (KYN; 1 mM; Sigma-Aldrich), 4-aminopyridine (4-AP; 5 µM; Sigma-
Aldrich), tetraethylammonium chloride (TEA; 10 µM; Sigma-Aldrich), picrotoxin 
(100 µM; Alomone Labs), and 4-Methoxy-7-nitroindolinyl-caged-L-glutamate (MNI 
caged glutamate; 250 µM; Tocris/BioTechne, Minneapolis, MN, USA). 
 
2.5 Statistical Analysis 
Recordings were analyzed using pClamp 10.6 (Axon Instruments), 
Minianalysis 6.0.7 (Synaptosoft, Decatur, GA), and Prism 8 (GraphPad Software, 
San Diego, CA). Within-cell analysis of multi-event recordings (e.g. EPSCs before 
and after drug application) was performed using the two-sample Kolmogorov-
Smirnov (K-S) test. Grouped analyses were performed using a Student’s T-test, 
Wilcoxon matched pairs test, or 1-way ANOVA, as appropriate. In vivo glucose 
measurements were analyzed using a repeated-measures 2-way ANOVA with 




3 FGF19 acts in the hindbrain to lower blood glucose 
concentration and alter excitability of dorsal vagal motor 
neurons in hyperglycemic mice 
3.1 Introduction 
Fibroblast growth factor 19 (FGF19) is a post-prandially released hormone 
that is closely linked to metabolic homeostasis. When administered to the lateral 
or 3rd cerebral ventricles (ICV), FGF19 improves insulin sensitivity, decreases food 
intake, and decreases blood glucose concentration in an insulin-independent 
fashion in both type I and type II diabetes models [198, 203]. Autonomic or 
neuroendocrine mechanisms have been proposed to mediate these effects [197, 
198, 202]. While previous studies have focused on the effects of FGF19 in the 
hypothalamus, studies identifying the direct actions of FGF19 in the brainstem 
dorsal vagal complex (DVC), the primary parasympathetic regulatory center, have 
not been performed. 
The DVC is principally comprised of the area postrema, nucleus tractus 
solitarius (NTS), and dorsal motor nucleus of the vagus (DMV). Vagal afferents 
convey viscerosensory information to second-order sensory neurons in the NTS, 
which integrate this information with neural input from other brain areas and effects 
of humoral factors. NTS neurons make excitatory and inhibitory connections with 
DMV motor neurons, whose axons comprise the efferent vagus nerve and regulate 
visceral homeostatic processes that regulate blood glucose concentration [37, 44, 
48, 71, 274-276].  
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The DVC contains fenestrated capillaries that allow diffusion of humoral 
components, potentially including peptides like FGF19, which might typically be 
excluded by the blood-brain barrier [56, 69]. DVC neurons respond to changing 
glucose concentration as well as several metabolic hormones, including leptin, 
insulin, glucagon, and GLP-1 [50, 70, 72, 79, 80]. Importantly, FGF receptors 1 
and 3 (FGFR1 and FGFR3) and β-klotho (an obligate co-receptor) are expressed 
in the DVC, which suggests that DVC neurons participate in endogenous FGF 
signaling [277-279].  Manipulation of neuronal activity in the DVC is directly linked 
to changes in blood glucose concentration [44, 48]. Thus, alteration of neuronal 
activity in this area by FGF19 could contribute to regulation of systemic blood 
glucose. This study tests the hypothesis that FGF19 affects neural excitability in 
the DVC to lower blood glucose concentration. Identifying antidiabetic effects of 
FGF19 in the brainstem will improve understanding of how blood glucose can be 
regulated via central mechanisms. 
 
3.2 Research Design and Methods 
3.2.1 Animals 
Experiments were performed on juvenile (3-8 weeks old) male and female 
FVB mice [FVB-Tg(GadGFP)4570Swn/J, FVB; The Jackson Laboratory, Bar 
Harbor, ME] housed in the University of Kentucky Division of Laboratory Animal 
Resources facilities under normal 14:10 light-dark conditions with food (Teklad 
2018) and water available ad libitum, except where noted. Roughly equal numbers 
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of males and females were used and results from both sexes were aggregated. 
The University of Kentucky Animal Care and Use Committee approved all animal 
procedures. 
To induce necrosis of insulin-secreting pancreatic ß-cells, mice were fasted 
for 6 hr prior to receiving an intraperitoneal injection (i.p.; 0.15 mL) of either citric 
acid vehicle (CA; 0.1 M) or streptozotocin in CA (STZ; 200mg/kg; Sigma-Aldrich, 
St. Louis, MO). After injection, mice were returned to their home cages. Blood 
glucose was monitored by tail lance (Nova Max Plus, Nova Diabetes Care, 
Billerica, MA), and animals were used for experiments after ≥5 days (range: 5-19 
days) of sustained hyperglycemia (≥300mg/dL) [280, 281]. Similar periods of 
continuous hyperglycemia have been associated with persistent changes in 
intrinsic and synaptic properties of NTS and DMV neurons [280-285]. Mice with 
sustained hyperglycemia after STZ injection were considered a model of early type 
1 diabetes mellitus (T1DM). 
3.2.2 Intracranial Injection 
Fasted mice (2 hr) were anesthetized using isoflurane (5% induction, 3% 
maintenance) and placed in a stereotaxic frame. Mice were kept on a heating pad 
during surgery to prevent hypothermia. The skull was exposed using a midline 
incision, and a ~2 mm diameter midline craniotomy was made 2mm posterior to 
lambda. Vehicle (VEH; 1 µL, PBS) or FGF19 (3 µg) in VEH was delivered to the 
fourth ventricle (4V) using a 5 µL syringe equipped with a 26 gauge flat-tipped 
needle (Hamilton, Reno, NV) over a period of 10 min. The needle was allowed to 
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stay in place for 3 min before withdrawing. After surgery, mice were returned to 
their home cage and given buprenorphine (0.1 mg/kg, analgesic). Mice recovered 
rapidly from surgery and resumed normal feeding behavior within 10 minutes of 
anesthesia withdrawal. Blood glucose was measured 30 min prior to and at 10 min 
and 6, 12, and 24 hr after 4V injection. The first post-surgery analysis time point 
(6hr) was chosen to allow for sufficient time to recover from surgery. Similar 
experiments were performed with the addition of (-)-scopolamine methyl bromide 
(methylscopolamine; MSA; 1 mg/kg; i.p) to block peripheral muscarinic receptors 
and consequent parasympathetic output [44]. MSA was administered 30 minutes 
prior to and every 2 hours after surgery until the conclusion of the experiment (6hrs 
post-surgery). 
3.2.3 Electrophysiology 
For complete methods, see general methods in Chapter 2. Seal resistance 
was typically 1-5 GΩ measured using square voltage steps applied through the 
recording pipette at 100 Hz. Acceptable series resistance was considered to be 
<25 MΩ (range=3.48-23.57 MΩ; mean=12.88±0.32 MΩ) and was regularly 
monitored; recordings were discarded if series resistance or cell capacitance 
changed by ≥ 20% during recording. 
FGF19 (ProspecBio, Ness Ziona, Israel) was bath applied at 230 pM. This 
concentration was shown to stimulate approximately half-maximal glucose uptake 
and phosphorylated extracellular signal-related kinase (pERK) induction in cell 
culture assays [286]. FGF19 was applied only once per slice to prevent the 
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influence of potential long-term effects. Added to the ACSF for specific 
experiments were the following: tetrodotoxin (TTX; 2 µM; Alomone Labs, 
Jerusalem, Israel), kynurenic acid (KYN; 1 mM; Sigma-Aldrich), 4-aminopyridine 
(4-AP; 5 µM; Sigma-Aldrich), tetraethylammonium chloride (TEA; 10 µM; Sigma-
Aldrich), and picrotoxin (100 µM; Alomone Labs). Incubation time for FGF19 was 
5 min; antagonists or channel blockers were applied for ≥10 min prior to and during 
agonist application.  
DMV neurons were identified by their morphology (>20 µm soma width, 
multipolar) and location in the slice [35, 55]. Once in whole-cell configuration, 
neurons were held near the resting membrane potential for 10 min to allow 
equilibration of the pipette solution and cytoplasm. Voltage values were corrected 
post-hoc to account for the liquid junction potential (-15 mV).  Excitatory post-
synaptic currents (EPSCs) were recorded at a holding potential of -85 mV and 
inhibitory post-synaptic currents (IPSCs) were recorded at a holding potential of -
15 mV. For event-based recordings (e.g., action potentials, EPSCs), 3 min of 
continuous activity (typically 300-3000 events) was examined. In these recordings, 
neurons were rejected if the initial event frequency was less than 0.4 Hz to ensure 
an adequate number of events for analysis. Input resistance (Rin) was measured 
in current-clamp mode from responses to 500 ms current steps ranging from -20 
to 0 pA in 5 pA increments; Rin was calculated as the slope of the line that best fit 
these points using linear regression. A peptide-induced change in input resistance 
of more than 20% was considered responsive. 
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Potassium currents were measured in neurons voltage-clamped at -75 mV 
using a voltage step protocol. The protocol consisted of a 500 ms step  to -125 
mV, followed by a 3000 ms depolarizing step to the test potential, after which the 
cell was returned to -75 mV. The test potentials ranged from -75 mV to +35 mV in 
10 mV increments. Peak current was measured at the first 50 ms of the 
depolarizing step and steady-state current was measured over the last 500 ms of 
the step, once the current had saturated. Peak values were recorded as the 
difference between peak and steady-state amplitudes within the same step. When 
the peak current was blocked (i.e. 4-AP or intracellular Cs+), only the steady-state 
value was measured.  
3.2.4 Immunofluorescence 
DMV neurons were recovered by staining for biocytin (0.2% added to the 
internal solution; Sigma-Aldrich). After recording, brainstem slices were fixed 
overnight in 4% paraformaldehyde in 0.15M phosphate buffer. Slices were rinsed 
3 times with 0.01 M phosphate buffered saline (PBS; Sigma-Aldrich) and 
immersed in avidin conjugated to AMCA Avidin-D (1:400; Vector Laboratories) in 
PBS containing 1% Triton X-100 for 3-4 hr at room temperature. Slices were then 
rinsed three times with PBS and then visualized to identify slices that contained 
biocytin-filled neurons. Slices containing biocytin-filled neurons were placed in a 
30% sucrose solution in PBS overnight for cryoprotection, sectioned on a cryostat 
at 20 µm thickness, and rinsed with PBS. The sections were then immersed in 5% 
normal goat serum in PBS for 30 minutes, then in PBS containing 1% normal goat 
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serum, 0.5% Triton X-100, and FGFR1 antibody (Rabbit mAB; 1:500; Cell 
Signaling Technologies 9740T; [287]) for 24 hr, rinsed for 15 minutes three times 
with PBS, and immersed in a goat anti-rabbit secondary antibody (1:400; 
Alexafluor 568; Invitrogen, Carlsbad, CA; [288]). Sections were washed again for 
15 minutes three times with PBS and then mounted on slides and air dried, 
covered with Vectashield H-1000 (Vector Laboratories, Burlingame, CA), and 
coverslipped.  Sections were visualized using epifluorescence (BX-41; Olympus) 
and imaged using a Spot RT camera and software (Diagnostic Instruments, 
Sterling Heights, MI). Final images were adjusted for brightness and contrast for 
illustrative clarity only. Omission of either the primary or secondary antibody 
resulted in no labeling (n=4). 
3.2.5 Statistics and Analysis 
Recordings were analyzed using pClamp 10.6 (Axon Instruments), 
Minianalysis 6.0.7 (Synaptosoft, Decatur, GA), and Prism 8 (GraphPad Software, 
San Diego, CA). Within-cell analysis of multi-event recordings (e.g. EPSCs before 
and after drug application) was performed using the two-sample Kolmogorov-
Smirnov (K-S) test. Grouped analyses were performed using a Student’s T-test, 
Wilcoxon matched pairs test, or 1-way ANOVA, as appropriate. In vivo glucose 
measurements were analyzed using a repeated-measures 2-way ANOVA with 





3.3.1 Hindbrain application of FGF19 decreases blood glucose 
concentration in hyperglycemic mice via a parasympathetic 
mechanism  
To determine whether FGF19 alters blood glucose concentration by 
interacting with the dorsal hindbrain, FGF19 (3 µg) was administered via 4V 
infusion in fasted control or STZ-treated mice with sustained (≥5 days), continuous 
hyperglycemia (i.e., T1DM mice). Blood glucose concentration was measured 2 
hr before injection (i.e., before fasting) and at 10 min, 6 hr, 12 hr, and 24 hr after 
4V administration.  In control mice, FGF19 did not significantly alter blood glucose 
concentration at any time point after injection, compared to vehicle (VEH; n = 12; 
p > 0.05; Figure 3.1A). In T1DM mice, FGF19 significantly decreased blood 
glucose concentration at 6 and 12 hrs post-4V administration, compared to VEH 
injection (6hr: VEH, 577.17 ± 21.273 mg/dL; FGF19, 349.66 ± 33.98 mg/dL; n = 
12; p < 0.01; 12hr: VEH, 577.67 ± 18.45 mg/dL; FGF19, 353.00 ± 41.763 mg/dL; 
n = 12; p < 0.01; Figure 3.1A). Blood glucose returned to pre-injection 
concentration by the 24-hour time point and was not statistically significant relative 
to VEH (p > 0.05). FGF19 also decreased the post-injection glucose area under 
the curve (AUC) in T1DM mice (VEH, 13,588 ± 467 mg•hrs/dL; FGF19, 9576 ± 
544 mg•hrs/dL; p < 0.0001; Figure 3.1B). FGF19 did not significantly alter AUC in 
control mice (VEH, 4170 ± 166 mg•hrs/dL; FGF19, 4233 ± 99 mg•hrs/dL; p > 0.05). 
FGF19 infusion into 4V therefore significantly reduced blood glucose 
concentration in hyperglycemic, but not normoglycemic mice. 
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Since 4V administration of FGF19, but not VEH, significantly reduced blood 
glucose concentration in T1DM mice, the involvement of parasympathethic output 
in the response was determined in a cohort of T1DM mice that were pre-treated 
with MSA (1 mg/kg; i.p.) prior to FGF19 application (Figure 3.1C; n = 5).  MSA 
blocks  peripheral muscarinic receptors mediating parasympathetic output to the 
viscera, but does not cross the blood-brain barrier to block central muscarinic 
receptors [289]. MSA may also prevent activation of sympathetic superior cervical 
ganglion neurons [290] and sympathetic activation can be associated with an 
increase in blood glucose concentration [291]. Considering this, a peripheral 
sympathetic blockade might be expected to decrease blood glucose. However, 
pretreatment with MSA in fasted T1DM mice was not found to significantly alter 
blood glucose concentration (Fasted, 544 ± 20.1 mg/dL; Fasted+MSA, 558 ± 35.7 
mg/dL; n = 5; p > 0.05; Figure 3.1C1). The effect of 4V administration of FGF19 
on blood glucose was abolished in mice pre-treated with MSA (p > 0.05; Figure 
3.1C), indicating that the glucose-lowering effects of 4V infused FGF19 were most 




Figure 3.1. Hindbrain application of FGF19 decreases blood glucose 
concentration in diabetic mice through a parasympathetic mechanism.   
(A) Blood glucose concentration measured 2 hours before injection (before 
fasting), and at 10 minutes, 6 hours, 12 hours, and 24 hours after fourth ventricle 
microinjection of VEH (1 µL PBS) or FGF19 (3 µg in VEH) in normoglycemic 
(control) and hyperglycemic mice with type 1 diabetes mellitus (T1DM). Asterisk 
indicates significance versus VEH for T1DM mice (**p < 0.01; n = 24; repeated 
measures 2-way ANOVA with Tukey’s multiple comparison test). (B) Post-
injection blood glucose area under the curve values calculated for the data shown 
in A. Asterisk indicates significance versus VEH (***p < 0.001; n = 24; 1-way 
ANOVA). (C1) Blood glucose concentrations measured at -2.5 hrs (fed), -30 
48 
 
minutes (fasted), -15 minutes (after MSA injection), 0 minutes, and 6 hours in 
relation to FGF19 injection (C2) Change in blood glucose from fed state to 6-hour 
time point. Pretreatment with systemic methylscopolamine (MSA) prevented the 
glucose lowering effect of FGF19. VEH and FGF19 group data were calculated 





3.3.2 Differential effects of FGF19 on synaptic excitability 
 Whole-cell patch-clamp recordings were made from DMV neurons in 
acutely prepared brainstem slices to assess the effects of FGF19 on excitatory 
synaptic transmission. DMV neurons were voltage-clamped at -85 mV and 
spontaneous EPSCs (sEPSCs) were recorded while bath-applying FGF19 (230 
pM; Figure 3.2). In neurons from control mice, FGF19 significantly decreased 
spontaneous EPSC (sEPSC) frequency in 4 out 8 neurons, determined by within-
recording K-S test.  Overall, mean sEPSC frequency was modestly, but 
significantly reduced (19%) by FGF19 (ACSF, 2.152 ± 0.44 Hz; FGF19, 1.807 ± 
0.37 Hz; n = 8; p < 0.05; Figure 3.2E). There was no significant effect of FGF19 
on sEPSC amplitude (ACSF, 21.45 ± 4.28 pA; FGF19, 22.91 ± 2.49 pA; n = 7; p 
> 0.05; Figure 3.2F).  
Consistent with previous reports, sEPSC frequency was significantly 
greater in DMV neurons from T1DM mice than in controls (p < 0.05) [282, 284]. In 
DMV neurons from T1DM mice, FGF19 consistently and significantly increased 
sEPSC frequency in each of 7 neurons (p < 0.02; K-S test; Figure 3.2E). Mean 
sEPSC frequency was significantly increased by 43% in the presence of FGF19 
(ACSF, 8.63 ± 1.57 Hz; FGF19, 12.33 ± 1.62 Hz; n = 7; p < 0.02; Figure 3.2E). 
There was no significant change in sEPSC amplitude (ACSF, 17.70 ± 2.34 pA; 
FGF19, 19.55 ± 3.52 pA; p > 0.05; Figure 3.2F).  Thus, FGF19 led to a modest, 
but significant decrease in excitatory synaptic input to DMV neurons in slices from 
normoglycemic mice, but the peptide further increased the already enhanced 
excitatory synaptic drive to DMV neurons from T1DM mice.  
50 
 
To determine whether the effects of FGF19 on EPSC frequency were due 
to activation of receptors located on presynaptic terminals, miniature EPSCs 
(mEPSCs) were recorded in the presence of TTX (2 µM), a blocker of action 
potential-dependent synaptic activity. In control mice, there was no significant 
change in mean mEPSC frequency during FGF19 application (ACSF, 4.26 ± 1.00 
Hz; FGF19, 4.00 ± 0.95 Hz; n = 7; p > 0.05; Figure 3.2G), although significant 
changes in frequency could be detected in four of seven neurons (increase, n = 2; 
decrease, n = 2; p < 0.02; K-S test).  There was no significant difference in mean 
mEPSC amplitude (ACSF, 12.4 ± 2.51 pA; FGF19, 12.2 ± 2.39 pA; n = 7; p > 0.05; 
Figure 3.2H).  
FGF19 also produced no significant change in overall mEPSC frequency in 
T1DM mice (ACSF, 7.93 ± 2.06 Hz; FGF19, 7.77 ± 2.14 Hz; n = 7; p > 0.05; Figure 
3.2G). In this group, only one neuron produced a significant change of mEPSC 
frequency as measured by the K-S test (p < 0.01). Similarly, there was no 
significant difference in mEPSC amplitude (ACSF, 12.9 ± 1.08 pA; FGF19, 13.1 ± 
1.05 pA; p > 0.05; Figure 3.2H).  FGF19 therefore modestly decreased excitatory 
synaptic input to DMV neurons in control mice, but significantly increased sEPSC 
frequency in DMV neurons from T1D mice, and these effects were mostly 
prevented when action potential-dependent synaptic activity was blocked.  
To assess possible effects of FGF19 on inhibitory synaptic activity, 
spontaneous IPSCs (sIPSCs) were recorded. No effects on sIPSC frequency were 
observed in control (ACSF, 4.19 ± 1.06 Hz; FGF19, 3.87 ± 1.16 Hz; n = 5; p > 
0.05) or T1DM mice (ACSF, 2.72 ± 1.07 Hz; FGF19, 2.53 ± 0.96 Hz; n = 5; p > 
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0.05). Additionally, baseline sIPSC frequency was not significantly different 
between the two groups (control; 4.19 ± 1.06 Hz; T1DM; 2.72 ± 1.07 Hz; p > 0.05; 
n = 10). Similarly, FGF19 did not change sIPSC amplitude in control (ACSF, 29.5 
± 3.67 pA; FGF19, 25.7 ± 4.56pA; n = 5; p > 0.05) or T1DM mice (ACSF, 33.5 ± 
1.74 pA; FGF19, 27.4 ± 3.56 pA; n = 5; p > 0.05). FGF19 therefore selectively 
modulated glutamate release in the DMV, being decreased in control and 





Figure 3.2. FGF19 decreases sEPSC frequency in neurons of the dorsal 
motor nucleus of the vagus (DMV) in slices from normoglycemic, control 
mice and increases sEPSC frequency in DMV neurons from hyperglycemic, 
T1DM mice.  
(A) Voltage clamp recordings of sEPSCs in a DMV neuron from a control 
mouse and (B) after addition of FGF19 (230 pM). (C) Recording of sEPSCs in a 
DMV neuron from a T1DM mouse and (D) in FGF19. Lower traces indicated by 
arrows in A-D are expanded from the area indicated with a bar in the top traces in 
each set; all sEPSC measurements were from neurons voltage-clamped at -85 
mV. (E) FGF19 significantly decreased mean sEPSC frequency in control mice (n 
= 8) and increased mean sEPSC frequency in T1DM mice (n = 7).  sEPSC 
frequency was significantly greater in neurons from T1DM mice than from control 
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mice (*p < 0.05; **p < 0.01; ***p < 0.001).  (F) FGF19 did not affect mean sEPSC 
amplitude in control (n = 8) or T1DM mice (n = 7; p > 0.05). sEPSCs were recorded 
from: Control; 2 male and 2 female; T1DM 3 male and 2 female mice. In the 
presence of tetrodotoxin (TTX; 2 µM), FGF19 did not affect mean mEPSC 
frequency (G) or amplitude (H) in control (n = 7; p > 0.05) or T1DM mice (n = 7; p 
> 0.05). mEPSCs were recorded from: Control; 2 male and 2 female; T1DM 2 male 




3.3.3 Effects on resting membrane potential and input resistance 
To confirm the presence of FGF receptors in DMV neurons, 
immunolabeling of FGFR1 was performed. Figure 3.3A shows an example of a 
biocytin filled DMV neuron and FGFR1-like immunoreactivity in the DVC. To 
investigate the effects of FGF19 on membrane properties of DMV neurons, input 
resistance (Rin) and resting membrane potential (RMP) were recorded in current-
clamp mode in the presence of TTX (2 µM) to prevent spontaneous action 
potentials (Figure 3.3B-G). Neither RMP nor Rin differed significantly between 
control and T1DM mice (p > 0.05). In control mice, FGF19 significantly 
hyperpolarized the RMP whereas in T1DM mice, FGF19 did not significantly alter 
mean RMP (Table 1). Despite the lack of an overall effect, 7/10 T1DM neurons 
were hyperpolarized by >3 mV, suggesting inhibition of most neurons.  In control 
mice, the overall effect of FGF19 on Rin was not significant, whereas in T1DM 
FGF19 significantly decreased overall Rin (Table 1). In DMV neurons from both 
control and T1DM mice, FGF19 induced a >20% decrease Rin in approximately 
half of neurons in each group. Excluding one neuron in the T1DM group that 
depolarized in response to FGF19, a decrease in Rin was always accompanied by 
a concomitant hyperpolarization of RMP, suggesting the opening of a channel at 
resting membrane potential. The predominant effects of FGF19 on RMP and Rin 
were therefore inhibitory, consisting of a membrane hyperpolarization and 






Figure 3.3. Effects on input resistance and resting membrane potential.   
(A) Fluorescence images showing a recorded, biocytin-filled DMV neuron 
(blue) and immunofluorescence staining for FGFR1 (red) at two magnifications. 
Arrow indicates an area of label overlap (purple), suggestive of FGFR1 localization 
on the recorded DMV neuron.  (B) Current injection recordings of DMV neurons 
from a control mouse and (C) T1DM mouse.  (D) I-V plots for responses of DMV 
neurons to FGF19 application from control mice (n = 9) and (E) T1DM mice (n = 
10). The slope of the lines in D and E reflect input resistance.  (F) FGF19 did not 
alter mean input resistance in control mice (n = 9; p > 0.05) but significantly 
decreased input resistance in T1DM mice (n = 10; *p < 0.05). (G) FGF19 
significantly hyperpolarized neurons from control mice (n = 9; **p < 0.01) but did 
not alter mean resting membrane potential in T1DM mice (n = 10; p > 0.05). All 
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recordings in TTX (2 µM). Recorded from: Control; 2 male and 2 female; T1DM 4 
male and 2 female mice. 
Table 3.1. Intrinsic membrane properties of DMV neurons in response to 
FGF19 
 Control Mice 
 ACSF ACSF+FGF19 pval n 
RMP (mV) -62.3±1.40 -69.3±1.92 p < 0.01 9 
Rin (MΩ) 1013±148 844±193 n.s. 9 
Action Potential Frequency 
(Hz) 0.99±0.112 1.12 ± 0.171 n.s. 14 
 
    
 T1DM Mice 
 ACSF ACSF+FGF19 pval n 
RMP (mV) -61.2±1.55  -64.7±2.10 n.s. 10 
Rin (MΩ) 964±109 771±142 p < 0.05 10 
Action Potential Frequency 







3.3.4 Action potential frequency 
To investigate the effects of FGF19 on spontaneous action potential current 
(IAP) frequency, neurons were recorded in cell-attached configuration (Figure 3.4). 
In control mice, there was no significant change in mean IAP frequency during 
FGF19 application (Table 1). However, IAP frequency in individual neurons was 
significantly altered (increased, n = 6; decreased n = 4; p < 0.02 K-S test). In T1DM 
mice, there was a significant decrease in mean IAP frequency during FGF19 
application (Table 1).  IAP frequency in individual neurons was predominantly 






Figure 3.4. FGF19 variably affects action potential frequency.   
(A) Representative traces showing effects of FGF19 on spontaneous 
sodium-dependent action potential currents (IAP) in cell-attached recordings in a 
DMV neuron from a control mouse. (B) Cumulative probability plot of the traces in 
A. (C) Representative traces showing effects of FGF19 on IAP frequency in a DMV 
neuron from a T1DM mouse. (D) Cumulative probability plot of the traces in C. (E) 
FGF19 did not alter mean IAP frequency in control mice (n = 14; p > 0.05) but 
significantly decreased IAP frequency in T1DM mice (n = 8; p < 0.05). Asterisk 
indicates significance versus ACSF.  (F) Relative proportion of neurons with 
responses to FGF19 application in neurons from control mice indicate variable 
responses.  (G) Proportions of responses in T1DM mice suggests a that FGF19 
decreases IAP frequency in most neurons.  Recorded from: Control; 2 male and 2 
female; T1DM 3 male and 2 female mice. 
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3.3.5 FGF19 decreases A-type K+ current amplitude in control, but not in 
T1DM mice 
Since inconsistent effects of FGF19 were observed on IAP firing, we 
investigated the possibility that FGF19 altered voltage-gated K+-current amplitude, 
in addition to its effects on passive membrane properties of DMV neurons. To 
determine the effects of FGF19 on voltage-gated K+ current amplitudes, a step 
protocol was performed in voltage-clamp mode in the presence of TTX (2 µM), 
PTX, a GABAA receptor blocker (100 µM) and KYN, an ionotropic glutamate 
receptor blocker (1 mM). To either block or help isolate the A-type current, ACSF 
included either 4-AP, an A-type current blocker (5 mM) or TEA, a delayed-rectifier 
current blocker (10 mM). To adjust for any potential differences in cell size, current 
values were normalized to cell capacitance to yield current density (pA/pF). 
In the presence of TEA, FGF19 significantly decreased the amplitude of the 
peak current density measured at 50 ms in DMV neurons from control mice (ACSF, 
50.5 ± 6.61 pA/pF; FGF19, 38.3 ± 5.46 pA/pF; n = 9; p < 0.05; Figure 3.5). Unlike 
in controls, FGF19 produced no significant change in peak current density in 
neurons from T1DM mice (ACSF, 65.7 ± 7.22 pA/pF; FGF19, 64.8 ± 6.04 pA/pF; 




Figure 3.5. FGF19 decreases A-type K+ current amplitude in DMV neurons 
from control, but not in T1DM mice.   
(A) Voltage activation step recording a from control mouse in ACSF and in 
the presence of FGF19 (230 pM). Traces shown are peak data only (i.e. steady 
state current has been subtracted). (B) Graphed peak current density data from 
control mice (n = 9) indicate an FGF19-mediated reduction in peak current density 
at potentials at and above -45 mV (*p<0.05). (C) Effect of FGF19 on peak current 
density for the +35 mV step for individual neurons (n = 9; *p < 0.05). (D) Voltage 
activation step recording from T1DM mouse in ACSF and in the presence of 
FGF19. (E) Peak current density in DMV neurons from T1DM mice (n = 8). (F) 
The effect of FGF19 on peak current density for the +35 mV step was not 
significant at any potential (n = 8; p>0.05). All recordings in tetrodotoxin (TTX; 2 
µM), picrotoxin (PTX; 100 µM), kynurenic acid (KYN; 1 mM), and 
tetraethylammonium (TEA; 10 µM). Recorded from: Control; 4 male and 3 female; 
T1DM 2 male and 2 female mice. 
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Since FGF19 only altered voltage-dependent K+ currents in DMV neurons 
from control mice, additional experiments to further identify the nature of this effect 
were restricted to this group. The effects on FGF19 on K+ current amplitude were 
blocked by 4-AP (ACSF, 106.0 ± 11.1 pA/pF; FGF19, 99.2 ± 11.6 pA/pF; n = 6; p 
> 0.05; Figure 3.6A-C) or when recording pipettes contained Cs+ (ACSF, 51.7 ± 
4.16 pA/pF; FGF19, 56.6 ± 3.20 pA/pF; n = 5; p > 0.05; Figure 3.6D-F).  FGF19 
therefore reduced the peak current amplitude of the 4-AP sensitive, putative A-





Figure 3.6. The effect of FGF19 on the A-type K+ current in normoglycemic 
mice is prevented by 4-AP or intracellular Cs+.    
(A) Representative voltage activation step recording in the presence of 4-
AP (5 mM). (B) Steady-state current density in DMV neurons from in the presence 
of 4-aminopyridine (4-AP; 5 µM; n = 6). (C) FGF19 effect on steady-state current 
density plotted for individual neurons from the 35 mV step in B (n = 6; p>0.05). 4-
AP recordings were from 2 male and 1 female mouse. (D) Representative voltage 
activation step recording using a Cs+ internal solution. (E) Steady-state current 
density in DMV neurons using a Cs+ internal solution (n = 5). (F) FGF19 effect on 
steady-state current density plotted for individual neurons from the 35 mV step in 
E (n = 5; p>0.05). Cs+ recordings were from 1 male and 1 female mouse. All 
recordings are from normoglycemic mice and performed in TTX (2 µM), PTX (100 




This report identifies the brainstem DVC as a previously underappreciated 
target for the antidiabetic effects of FGF19. Previous research on the metabolic 
effects of centrally applied FGF19 has focused on hypothalamic circuits, since 
third ventricle administration led to lower blood glucose levels that were correlated 
with decreased plasma ACTH and suppression of AgRP/NPY neuron activity [202, 
203]. The DVC contains FGFR1, FGFR3, and ß-klotho, suggesting that DVC 
neurons can respond to exogenous FGF and engage in endogenous FGF 
signaling [277-279].  Importantly, DVC neurons regulate autonomic control of 
HGP, food intake, and hepatic enzyme expression [44, 47, 292-294], all of which 
are mechanisms proposed to mediate the antidiabetic actions of ICV FGF19 [197, 
198, 203]. While the findings from previous studies are consistent with the 
hypothesis that FGF19 regulates metabolism and interacts with hypothalamic 
neurons, the present data suggest that actions of the peptide in the DVC may be 
sufficient to produce significant effects on systemic glucose concentration under 
hyperglycemic conditions.   
The effects of FGF on hypothalamic neurons could also function to lower 
blood glucose levels by signaling through the DVC and vagus nerve [47, 90]. ICV 
FGF19 activation of hypothalamic neurons decreases DVC c-fos expression and 
vagus nerve activity in response to neuroglucopenia [295]. Furthermore, some 
reports suggest that hypothalamic regulation of HGP works through DVC neuron 
activation and requires an intact vagus nerve [47, 92]. Consequently, interactions 
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of FGF19 with DVC circuits may provide a more direct path for FGF19-mediated 
antidiabetic effects. 
Acute 4V administration of FGF19 produced a significant, reversible 
decrease in blood glucose concentration in hyperglycemic mice for at least 12 
hours. Consistent with the effects of FGF19 application in the diencephalon, the 
glucose-lowering ability of FGF19 applied to the hindbrain was only observed in 
hyperglycemic mice [246, 296]. The effects on blood glucose are unlikely to the 
result of anesthesia or recovery from surgery, as all mice resumed normal feeding 
behavior rapidly after surgery and returned to baseline glucose levels, except the 
T1DM-FGF19 group. Diffusion of FGF19 to the hypothalamus is unlikely, as 
cerebrospinal fluid flows rostrocaudally and FGF19 was injected slowly into 4V to 
prevent backflow rostrally [297]. To wit, 4V application is often used as a substitute 
for direct DVC parenchymal injections [74, 85, 293, 298]. Altered activity of DMV 
motor neurons has been linked with blood glucose regulation, which is mediated 
by parasympathetic regulation of pancreatic and hepatic vagal activity [44, 48, 71].  
Moreover, the effect of 4V FGF19 on blood glucose was prevented when 
peripheral muscarinic receptors were blocked by MSA, suggesting a 
parasympathetic mechanism. Previous studies did not reach a consensus 
regarding the mechanism by which FGF19 decreases blood glucose in diabetic 
mice. Taken together, they suggest that FGF19 in the brain may work by altering 
hepatic metabolism with no effects on insulin or glucagon levels [186, 198, 203]. 
However, no further investigation into this mechanism was performed here. While 
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insulin is unlikely to play a role due to the use of a T1DM model, we cannot rule 
out the potential involvement of glucagon in the response to FGF19.  
A previous report found that third-ventricular FGF19 was able to decrease 
blood glucose concentration by >200 mg/dL in T1DM rats – similar in magnitude 
to the results found here - and this was associated with a 50% decrease in HGP 
[203]. Manipulation of DVC neuron excitability has been shown to decrease HGP 
by ~50% [47, 48, 92, 293], suggesting that FGF19 modulation of DVC excitability 
can alter HGP sufficiently to produce the decrease in blood glucose shown in 
Figure 3.1. Notably, the largest proportion of DMV neurons project to the stomach 
[29]. Since FGF19 altered excitability of most DMV neurons, this suggests effects 
on GI function, which may alter blood glucose indirectly and warrants further 
research. While this study was performed in a T1DM mouse model, similar results 
would likely be found in a type II diabetes (T2DM) model, since previous reports 
indicate that FGF19 functions independently of insulin to lower blood glucose 
concentration in both T1DM and T2DM models [198, 203].  The reduced insulin 
availability in this model of hyperglycemia is consistent with an insulin-
independent effect of FGF19 acting in the DVC.  The FGF19 effects in the 
hindbrain neurons are therefore sufficient to lower systemic glucose concentration 
in hyperglycemic mice. 
FGF19 produced a complex set of electrophysiological responses in DMV 
neurons that differed as a function of disease state (i.e. presence or absence of 
hyperglycemia). While FGF19 modestly decreased action potential-dependent 
glutamate release onto DMV neurons from control mice, it produced a robust and 
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consistent increase in synaptic excitation of DMV neurons from T1DM mice. The 
FGF19-mediated effects on glutamate release are mainly due to activity of the 
peptide on action potential firing of neurons with intact projections to the DMV, 
since blockade of action potentials with TTX prevented the overall effect of FGF19 
on glutamate release. Interestingly, analysis of IPSC frequency and amplitude 
revealed no significant effect of FGF19 on GABA release, suggesting relatively 
selective effects of the peptide on upstream excitatory circuits.  Because intact 
NTS neuron projections to the DMV are contained within the slice [299], and 
FGFRs are present in the NTS [277, 279], it is likely that FGF19 increases activity 
of premotor, glutamatergic NTS neurons to affect increased synaptic excitability 
of vagal motorneurons in the DMV of T1DM mice, but effects on other local circuits 
cannot be discounted.  Thus, the effects of FGF19 appear to impinge on central 
vagal circuitry that participates in vago-vagal reflexes, possibly including the gut-
brain-liver glucose regulatory circuit [300]. Phasic glutamatergic input profoundly 
affects vagal motor activity in vitro [21, 37], injection of glutamatergic agonists into 
the DVC lowers HGP [48], and blockade of glutamate receptors in the NTS 
prevents vagally-mediated, reflexive modulation of hepatic gluconeogenesis  
[300]. Glutamate release is persistently increased in the DMV of T1DM mice, and 
NMDA receptor function in glutamatergic NTS neurons is enhanced [282, 284]. 
Glutamate system plasticity in the DVC could also underlie the differences in 
FGF19 effects on EPSC frequency between control and T1DM mice.  
Consequently, the effect of FGF19 on EPSC frequency in T1DM mice may prove 
to be the primary determinant of its effects on blood glucose.   
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The effect of FGF19 on intrinsic excitability in DMV neurons was 
inconsistent and modest. In control mice, FGF19 produced mixed effects on action 
potential firing, whereas it mainly decreased firing in T1DM mice. Most neurons 
from both groups displayed a decrease in Rin and membrane hyperpolarization in 
response to FGF19 application. While these effects tend to be inhibitory, FGF19 
also decreased the magnitude of an A-type K+ current in control mice. Where the 
decreased synaptic excitation and generally inhibitory effect on RMP and Rin by 
FGF19 in control mice suggest a decrease in cellular excitability, the decrease in 
A-type K+ current might contribute to increased AP firing during periods of 
membrane depolarization [301]. Due to recording constraints, effects on PSCs, 
intrinsic membrane properties, APs, and A-type K+ channels were recorded 
separately. Thus, opposing pre and post-synaptic effects were not observed within 
the same neuron. DMV neurons display considerable heterogeneity regarding 
morphological and electrophysiological properties that may also contribute to their 
considerable variation in response to FGF19 [53, 55]. Notably, the inhibitory 
effects on DMV EPSC frequency and Rin in control mice are shared with both leptin 
and insulin [49, 50]. The marked FGF19-induced increase in synaptic excitability 
in DMV neurons from T1DM mice suggests that this factor may underlie the 
differential effects of the peptide on blood glucose in T1DM mice. 
It is not fully understood how DMV activity corresponds to changes in blood 
glucose. The increase in sEPSC frequency in DMV neurons from T1DM mice 
reported here and previously may represent a compensatory response to 
hyperglycemia [282, 284]. This suggests a model where an increase in synaptic 
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excitation of DMV motor neurons results in decreased blood glucose 
concentration. Correspondingly, microinjection of NMDA in the DVC decreases 
HGP [48]. This model is also consistent with our previous findings showing that 
increased synaptic inhibition of DMV neurons by depolarization of GABAergic 
afferents results in increased blood glucose in mice [44].  Here, FGF19 increased 
the already elevated sEPSC frequency in T1DM mice, which would be predicted 
to decrease blood glucose in this model.  
Diabetic hyperglycemia leads to profound changes in synaptic activity and 
postsynaptic responsiveness in the DVC, including increased glutamate release 
in the DMV and increased NMDA receptor function in the NTS [282-284]. This 
plasticity of excitatory circuitry in the DVC may contribute to the different metabolic 
and neuronal responses in hyper- and normoglycemic mice. The nature of the 
differences in electrophysiological effects between disease groups (e.g. diabetes 
reversed and amplified effects on sEPSCs while abolishing effects on A-type K+ 
currents) suggests that hyperglycemia may differentially regulate discrete 
intracellular pathways downstream from the FGFR. Indeed, FGFRs signal via 
MAP kinases, PLC𝛾𝛾, and PKC[123], all of which are also modulated by 
hyperglycemia/diabetes [302-304]. In addition, FGFRs signal through the PI3K-
Akt pathway, which is dysregulated in the brains of diabetic rats [305]. Moreover, 
the insulin receptor and FGFR share several intracellular signaling pathways that 
likely exhibit significant crosstalk [123, 306, 307]. Since the DVC responds to 
insulin [50, 293] and changing glucose concentrations [70, 276], and has access 
to circulating insulin and glucose via local fenestrated capillaries [56], it is to be 
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expected that the changes in peripheral metabolism in T1DM mice would produce 
profound effects on FGFR signal transduction in the DVC. Thus, differential 
responses to FGFs between disease groups may be linked to diabetes-induced 
changes in the intracellular pool of signaling machinery. As such, future study is 
warranted to investigate this possibility.  
The cellular responses of DMV neurons confirm that FGF19 modulates 
DMV neuron excitability, consistent with the hypothesis that FGF19 normalizes 
blood glucose in T1DM mice by altering autonomic output to the viscera. Despite 
this, it cannot be discounted that the antidiabetic effects found here could be 
partially mediated through interactions with other brain areas, since the NTS 
communicates with neurons in hypothalamic and ventral brainstem areas that 
regulate sympathetic and neuroendocrine functions, in addition to the DMV [90, 
308, 309]. However, MSA blocked the antidiabetic actions of FGF19, suggesting 
a predominantly parasympathetic mechanism.  
In conclusion, this study identified the dorsal hindbrain as a novel target 
tissue for the glucose-lowering effects of centrally acting FGF19 in hyperglycemic 
mice. The cellular and synaptic effects of FGF19 on DMV neurons were consistent 
with a parasympathetically-mediated effect on blood glucose in T1DM mice.  This 
research highlights the importance of the DVC in FGFR-mediated glucoregulation 
and suggests that understanding FGF activity in central vagal circuitry may reveal 





4 Fibroblast growth factor 19 increases the excitability of pre-
motor glutamatergic neurons in the dorsal vagal complex of 
hyperglycemic mice 
4.1 Introduction 
Fibroblast growth factor 19 (FGF19) is an ileal-derived protein hormone that 
produces potent, anti-diabetic, and anti-obesogenic effects. Although early work 
suggested that these effects could be mediated by FGF19 acting on peripheral 
targets, several reports have now found that acute intracerebroventricular (ICV) 
administration of FGF19 may act at multiple distinct sites in the brain to regulate 
energy balance. Lateral ventricle administration of FGF19 increases metabolic 
rate [186], while 3rd ventricular administration was found to decrease food intake, 
lower insulin resistance, improve glucose tolerance, and reduce blood glucose 
concentrations in rodent models of diabetes and obesity [198, 202, 203, 217]. 
These findings suggest a hypothalamic mechanism since FGF19 was found to 
suppress AGRP/NPY activity [202] and decrease plasma ACTH [203]. However, 
we demonstrated that 4th ventricular administration of FGF19 also decreases 
blood glucose in type 1 diabetic (T1DM) mice, suggesting the hindbrain as an 
underappreciated target tissue for this system [51]. 
 The brainstem dorsal vagal complex (DVC) is an important 
homeostatic regulatory center that tightly controls parasympathetic output in 
response to numerous convergent inputs, both neuronal and humoral. The DVC 
is principally comprised of the area postrema (AP), the nucleus tractus solitarius 
(NTS), and the dorsal motor nucleus of the vagus (DMV). The NTS integrates 
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vagal afferent, viscerosensory information with input from several brain areas, 
including the hypothalamus and AP [37, 67, 89, 310]. In turn, the NTS regulates 
neural activity in the DMV through both glutamatergic and GABAergic projections 
[54, 299]. Finally, DMV neurons project cholinergic outputs through the efferent 
vagus nerve to regulate hepatic glucose production, gastric motility, and 
pancreatic exocrine secretion, among other visceral regulatory functions [44, 48, 
71, 274, 276, 311]. Additionally, the AP and NTS contain fenestrated capillaries 
that permit the passage of humoral components that may be excluded by the 
blood-brain barrier elsewhere [56, 69]. DVC neurons respond to many primary 
metabolic hormones including insulin, leptin, ghrelin, glucagon, GLP-1 [50, 72, 79, 
81, 86] and importantly, FGF19 [51]. The DVC, especially the AP and NTS, 
contains multiple FGF receptors (FGFR) as well as ß-klotho, an obligate co-
receptor [277-279], suggesting that neuronal activity in the DVC may regulate 
metabolic homeostatic mechanisms in response to endogenous FGF signaling. 
 In a mouse model of type 1 diabetes (T1DM), FGF19 consistently 
and robustly increased action potential-dependent excitatory synaptic 
transmission to the DMV [51]. This suggests that FGF19 alters the excitability of 
glutamatergic neurons immediately afferent to the DMV, which remain intact in the 
slice preparation. A likely source of these glutamatergic inputs is the NTS since 
the NTS to DMV connection is well documented [299, 312-314] and is open to 
modulation via various other peptides and neurotransmitters [49, 314-316]. 
Interestingly, receptor expression data suggest that the AP could also be a target 
for FGF19 since the AP expresses significantly more FGFR than surrounding 
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areas [277] and expresses more ß-klotho and FGFR2 than any other brain area, 
in addition to high levels of FGFR1 and FGFR3 [278]. Moreover, glutamatergic AP 
neurons project extensively to the NTS and DMV [68]. Taken together, these 
findings suggest that FGF19 may act on intrinsic DVC circuitry to modify synaptic 
input to the DMV and consequently modulate vagally-mediated glucoregulation. 
 This study tests the hypothesis that FGF19 increases excitatory 
neurotransmission in the DVC by altering excitability of NTS and AP neurons. In 
addition to functioning within local DVC circuits, the NTS and AP communicate 
bidirectionally with other brain areas thought to be involved in regulating energy 
metabolism [67, 88, 89]. Thus, FGF19-mediated alteration of excitability in these 
areas is likely to have wide-reaching metabolic effects by modulating vago-vagal 
circuit dynamics as well as influencing other brain areas that regulate ingestive 
behaviors and energy balance through autonomic or neuroendocrine means. 
4.2 Materials and Methods 
4.2.1 Animals 
All mice used for experiments were juvenile (3-8 weeks old) male and 
female FVB mice (FVB-Tg(GadGFP)4570Swn/J, FVB; Jackson Laboratory, Bar 
Harbor, ME, USA). This mouse expresses enhanced green fluorescent under the 
control of the GAD67 promoter and allows for the visual identification of 
GABAergic neurons. Animals were housed under 14:20 light-dark conditions in 
the University of Kentucky Division of Laboratory Animal Resources facilities with 
food and water available ad-libitum. Approximately equal numbers of both sexes 
73 
 
were used and results from both sexes were aggregated. All animal procedures 
were approved by the University of Kentucky Animal Care and Use Committee. 
To destroy insulin-secreting pancreatic β-cells, mice were given an 
intraperitoneal injection of streptozotocin (STZ; 200 mg/kg in 0.15mL of 0.1 M citric 
acid; Sigma-Aldrich, St. Louis, MO, USA) after a 6-hour fast. After injection, mice 
were returned to their home cages and blood glucose was monitored daily by tail 
lance (Nova Max Plus, Nova Diabetes Care, Billerica, MA, USA). Mice were used 
for experiments after ≥5 days of hyperglycemia (≥ 300 mg/dL). It has been 
previously established that a similar period of hyperglycemia is sufficient to 
produce lasting changes in both synaptic and intrinsic properties of NTS and DMV 
neurons [280-285]. Mice that displayed persistent hyperglycemia after STZ 
injection were considered a model of T1DM. 
 
4.2.2 Electrophysiology 
Mice were anesthetized using isoflurane inhalation (confirmed using foot 
pinch response) and decapitated. The brain was then rapidly removed and placed 
in ice-cold, oxygenated (2-4 °C; 95% O2/5% CO2) artificial cerebrospinal fluid 
(ACSF). In all experiments (except where the addition of drugs is noted), ACSF 
was composed of (in mM): 124 NaCl, 3 KCl, 26 NaHCO3, 1.4 NaH2PO4, 11 
glucose, 1.3 CaCl2, and 1.3 MgCl2. The hindbrain was mounted to a sectioning 
stage via cyanoacrylate glue and submerged in ACSF. Coronal brainstem slices 
(300 µm) were made using a vibratome (Series 1000; Technical Products 
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International, St. Louis, MO, USA). After cutting, slices were incubated in a holding 
chamber for 1 hour in warmed (30°C-35°C), oxygenated ACSF.  
For recordings, slices were transferred to a recording chamber on a fixed-
stage, upright microscope (BX51WI; Olympus, Melville, NY, USA) and superfused 
with warmed ACSF (32-34 °C). Whole-cell patch-clamp recordings were 
performed under visual control and cells were identified using infrared illumination 
with differential interference contract optics.  Glass recording pipettes (1.65 mm 
OD, 1.2 mm ID; King Precision Glass, Claremont, CA, USA) were filled with 
internal solution that contained (in mM): 130 K-gluconate, 1 NaCl, 5 EGTA, 10 
HEPES, 1 MgCl2, 1 CaCl2, 3 KOH, and 2 Mg-ATP; pH = 7.2-7.3, adjusted with 5 
M KOH. using a Multiclamp 700B amplifier, Digidata 1440A digitizer, and pClamp 
10.6 software (Molecular Devices, Axon Instruments, Sunnyvale, CA, USA). Data 
were recorded at 20 kHz and filtered at 3 kHz. 
Added to the ACSF for specific experiments were the following: fibroblast 
growth factor 19 (FGF19; 230 pM; ProspecBio, Ness Ziona, Israel), 4-Methoxy-7-
nitroindolinyl-caged-L-glutamate (MNI caged glutamate; 250 µM; 
Tocris/BioTechne, Minneapolis, MN, USA), tetrodotoxin (TTX; 2μM; Alomone 
Labs, Jerusalem, Israel), and picrotoxin (100 μM; Alomone Labs). The 
concentration for FGF19 was chosen because we have previously shown that this 
concentration alters intrinsic and synaptic properties of DMV neurons [51]. 
Additionally, this concentration has been shown to stimulate approximately half-
maximal glucose uptake and phosphorylated extracellular signal-related kinase 
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(pERK) induction in cell culture assays [286]. FGF19 was applied for 5 minutes 
and was applied once per slice to avoid any lasting effects of prior applications.  
DMV neurons were identified via morphology (elongated, tear-drop-shaped 
soma ≥ 20 µm) and by their location in the slice (located along the ventral edge of 
the DVC). NTS neurons were also identified by morphology and location in slice 
(dorsal to the DMV). The mouse model used here expresses enhanced green 
fluorescent protein (EGFP) under a GAD67 promoter. This allows for visual 
identification of a large proportion of GABAergic NTS neurons. Since previous 
research suggested that FGF19 altered glutamatergic but not GABAergic 
transmission in the DVC, EGFP-negative NTS neurons were targeted to increase 
the likelihood of recording from a glutamatergic neuron [51].  
Once whole-cell configuration was achieved, neurons were held near their 
resting membrane potential (RMP) for at least 5 minutes to allow proper 
equilibration of the cytoplasm and pipette solution. Acceptable series resistance 
was considered to be <25 MΩ (range = 6.044-24.89 MΩ; mean = 13.21 MΩ) and 
was regularly monitored; recordings were discarded if series resistance or cell 
capacitance changed by ≥ 20% during recording. All voltage values were 
corrected post-hoc for the liquid junction potential (calculated at -15 mV). 
Excitatory postsynaptic currents (EPSCs) were recorded at -85 mV, the 
approximate reversal potential for Cl-, to prevent interference by inhibitory 
currents. For continuous recordings of EPSCs, 2 min of activity was analyzed. 
Input resistance (Rin) was calculated as the slope of the line that best fit the points 
produced by 500 ms negative current injections ranging from -20 pA to 0 pA in 5 
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pA increments. Neurons were considered responsive if FGF19 produced a ≥20% 
change in Rin. Current versus action potential frequency (I-F) analysis was made 
in the same group of neurons that were used to measure Rin by measuring action 
potentials resulting from positive current injections ranging from 0 pA to 20 pA in 
5 pA increments. 
Similar to previous reports of glutamate photoactivation in the DVC [49, 
299, 316], MNI-caged glutamate (250 µM) was added to recirculating ACSF and 
uncaged using 30 ms pulses of UV light (UV filter; Chroma Technology, 
Rockingham, VT). UV light, controlled by an automated shutter system (Uniblitz 
VMM-D1, Vincent Associates, USA), was directed to the slice through the 40X 
water immersion objective. Aperture width was set to minimum to stimulate a small 
patch of neurons (approximately 75 µm diameter stimulation region). When light 
was positioned directly over the recorded cell, UV pulses produced large, fast 
inward currents in voltage-clamp mode and significant depolarization in current-
clamp mode (typically >200 pA and >20 mV, respectively). To find extant 
glutamatergic connections, the objective was systematically moved throughout the 
AP or NTS until the UV pulse produced a detectable synaptic response. 
Recordings consisted of 10 repetitions of: A 1-second pre-stimulus period, a 30 
ms UV pulse, then a 2-second post-stimulus period. Results were reported as a 
difference in EPSC frequency during the 500 ms immediately after stimulation 
versus that in the 1-second period before stimulation. Successful glutamate 




4.2.3 Statistics and Analysis 
Recordings were analyzed using pClamp 10.6 (Axon Instruments), 
Minianalysis 6.0.7 (Synaptosoft, Decatur, GA, USA), SAS 9.4 (SAS Institute, Cary, 
NC, USA) and Prism 8 (GraphPad Software, San Diego, CA, USA). Within-cell 
analysis of multi-event recordings (e.g., EPSCs before and after drug application) 
was performed using the 2-sample Kolmogorov-Smirnov (K-S) test. Grouped 
analyses were performed using a paired t-test when one before/after pair was 
present or repeated measures generalized linear mixed model with Tukey multiple 
comparisons when multiple before/after pairs were present. Significance was set 
at p<0.05 for all analyses. 
4.3 Results 
4.3.1 FGF19 increases the excitability of glutamatergic AP and NTS neurons 
that project to the DMV in hyperglycemic mice 
Previous reports found that FGF19 increased action potential-dependent 
glutamate release in the DMV of hyperglycemic, but not normoglycemic mice [6]. 
Both the NTS and area postrema (AP) remain intact in the slice preparation, 
express abundant FGF receptors, and have glutamatergic projections to the DMV 
[26, 28, 35]. Thus, it was posited that these areas were likely sources of excitatory 
input that was modified by FGF19. To identify the effect of FGF19 on excitatory 
neurotransmission from the NTS and AP to the DMV, glutamate photostimulation 
was made in these areas while recording EPSCs in DMV neurons (Fig 4.1). Briefly, 
the effect of glutamate uncaging was determined by measuring the difference in 
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EPSC frequency before and after UV light pulses. All recordings were made in the 
presence of picrotoxin (100 µM), a GABA receptor type-A blocker, to prevent 
network effects caused by stimulating local GABAergic neurons. 
When glutamate photostimulation was performed in the NTS of control 
mice, FGF19 failed to alter the mean effect of glutamate photostimulation in the 
NTS on EPSC frequency in the DMV (ACSF: 5.78 ± 1.05 Hz; FGF19: 5.81 ± 1.38 
Hz; n = 7; p>0.05). Since there was no overall effect on the response to 
photostimulation in the NTS, and since there was no effect of FGF19 on 
spontaneous EPSC (sEPSC) frequency in DMV neurons from control mice 
previously [6], no further uncaging experiments were performed in this group. 
When glutamate photoactivation was performed in the NTS of T1DM mice, FGF19 
significantly increased the mean effect of glutamate photostimulation in the NTS 
on EPSC frequency in the DMV (ACSF: 5.18 ± 1.02 Hz; FGF19: 7.52 ± 0.91 Hz; 
n = 10; p<0.05). This represented an average 1.84-fold increase in the response. 
Similarly, when glutamate photolysis was performed in the AP in T1DM mice, 
FGF19 significantly increased the mean effect of glutamate photostimulation 
(ACSF: 3.62 ± 0.82 Hz; FGF19: 8.16 ± 1.21 Hz; n = 5; p<0.01). This represented 
an average 2.6-fold increase in the response. Together, these data suggest that 
FGF19 increases the excitability of glutamatergic neurons in the AP and NTS that 





Figure 4.1. FGF19 increases the excitability of glutamatergic AP and NTS 
neurons that project to the DMV in hyperglycemic mice.  
(A) Diagram showing a typical stimulation and recording location for cells in B and 
C. (B) Representative voltage clamp recordings of evoked EPSCs for the NTS to 
DMV circuit in control mice. (C) Evoked EPSC response in this group before and 
after addition of FGF19 (230 pM; n = 7; p > 0.05). (C) Diagram showing a typical 
stimulation and recording location for cells in E and F. (E) Representative voltage 
clamp recordings of evoked EPSCs for the NTS to DMV circuit in T1DM mice. (F) 
Evoked EPSC response in this group before and after addition of FGF19 (n = 10; 
*p<0.05). (G) Diagram showing a typical stimulation and recording location for 
cells in H and I. (H) Representative voltage clamp recordings of evoked EPSCs 
for the AP to DMV circuit in T1DM mice. (I) Evoked EPSC response in this group 
before and after addition of FGF19 (n = 5; **p<0.01). In representative traces, blue 
80 
 
rectangle indicates stimulation time and duration. Arrows point to an expanded 
trace showing 500 ms before and after stimulation. All cells recorded at -85 mV.  
 
4.3.2 FGF19 produces mixed effects on intrinsic excitability of NTS 
neurons. 
To determine the effects of FGF19 on intrinsic excitability of NTS neurons, 
resting membrane potential (RMP) and input resistance (Rin) were measured in 
current-clamp mode (Fig 4.2A-4.2F). Recordings were performed in control and 
T1DM mice to understand whether hyperglycemia modulates the effect of FGF19 
in these neurons as suggested by previous findings [6]. A neuron that displayed a 
>20% change in Rin or >2 mV change in RMP was considered responsive to 
FGF19. In neurons from control mice, FGF19 modestly but significantly decreased 
mean Rin (ACSF: 1.38 ± 0.07 GΩ; FGF19: 1.21 ± 0.07 GΩ; n = 60; p<0.01). In this 
group, FGF19 produced a change in Rin in approximately 50% of neurons, with 
lower Rin observed in most responding neurons (8 increased; 21 decreased; 31 
no change). FGF19 did not alter mean RMP in NTS neurons from control mice 
(ACSF: -63 ± 1.22 mV; FGF19; -63.6 ± 1.29 mV; n = 60; p < 0.05), but individual 
neurons responded with a change in RMP in similar proportions to those observed 
with Rin (8 increased; 16 decreased; 36 no change). In neurons from T1DM mice, 
FGF19 produced a similarly small but significant decrease in mean Rin (ACSF: 
1.51 ± 0.11 GΩ; FGF19: 1.33 ± 0.14 GΩ; n = 26; p<0.05). In this group, FGF19 
altered Rin in 50% of neurons with a predominately inhibitory effect in responding 
neurons (2 increased, 11 decreased, 13 no change). FGF19 also mildly 
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hyperpolarized the mean RMP in this group (ACSF: -59.5 ± 1.37 mV; FGF19: -
62.3 ± 1.72 mV; n = 26; p<0.001).  
Similarly to Rin, FGF19 altered RMP in approximately half of neurons (0 
increased, 12 decreased, 14 no change). Neither Rin nor RMP differed between 
control and T1DM groups prior to FGF19 application. To identify the effects of 
FGF19 on action potential (AP) responsiveness in the NTS, positive current step 
recordings were performed in the same neurons to produce evoked APs (Fig 
4.2G-4.2J). In neurons from control mice, FGF19 decreased mean AP frequency 
at the 10 pA current step (n = 60; p<0.05; paired t-test). In neurons from T1DM 
mice, FGF19 decreased mean AP frequency at the 10, 15, and 20 pA current 





Figure 4.2. FGF19 produces mixed effects on intrinsic excitability of NTS 
neurons.  
Representative current step recordings in current clamp mode from (A) 
control and (B) T1DM mice. (C) FGF19 significantly decreased mean input 
resistance in both control (n = 60; **p<0.01) and T1DM mice (n = 26; *p<0.05). (D) 
FGF19 did not alter mean resting membrane potential in control mice (n = 60; 
*p>0.05) but significantly hyperpolarized mean RMP in T1DM mice (n = 26; 
***p<0.001). (E) Averaged current-voltage relationship in seen control mice (n = 
60). (F) Averaged current-voltage relationship seen in T1DM mice (n = 26). 
Representative traces showing action potential response to positive current 
injections in control (G) and T1DM mice (H). (I) Averaged action potential 
frequency response to positive current injections in control mice (n = 60; p<0.05). 
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(J) Averaged action potential frequency response to positive current injections in 
T1DM mice (n = 26; p<0.05). For all panels, * indicates p<0.05; ** indicates 
p<0.01, ***indicates p<0.001. 
4.3.3 FGF19 increases sEPSC frequency in NTS neurons from T1DM mice.  
Because FGF19’s effects on intrinsic excitability were inconsistent with its 
effects on spontaneous EPSC frequency reported previously in DMV neurons [6], 
and since FGF19 consistently increased EPSCs in the DMV after glutamate 
photolysis in either the NTS or AP, excitatory neurotransmission to NTS neurons 
was measured. To assess this, NTS neurons were voltage-clamped at -85 mV to 
record sEPSCs before and after bath application of FGF19 (Fig 4.3). In neurons 
from control mice, FGF19 did not significantly alter mean sEPSC frequency 
(ACSF: 3.02 ± 0.51 Hz; FGF19: 2.89 ± 0.47 Hz; n = 14; p>0.05). In this group, 
FGF19 altered sEPSC frequency in 7 out of 14 neurons (2 increased; 5 decreased; 
p < 0.02; within recording K-S test). FGF19 also failed to produce effects on mean 
sEPSC amplitude in this group (ACSF: 14.4 ± 1.04 pA; FGF19: 14.0 ± 1.07 pA; n 
= 14; p > 0.05).  In neurons from T1DM mice however, FGF19 significantly 
increased mean sEPSC frequency (ACSF: 3.60 ± 0.43 Hz; FGF19: 4.62 ± 0.57 
Hz; n = 13; p<0.001). In this group, FGF19 altered sEPSC frequency in all 
neurons, with a predominately excitatory effect (11 increased; 2 decreased; 
p<0.02; K-S test). FGF19 did not alter mean sEPSC amplitude in this group 
(ACSF: 17.7 ± 1.31 pA; FGF19: 15.3 ± 1.09 pA; n = 13; p > 0.05). Neither sEPSC 
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frequency nor sEPSC amplitude differed between the control and T1DM groups 
prior to FGF19 application. 
 
 
Figure 4.3. FGF19 increases sEPSC frequency in NTS neurons from T1DM 
mice.  
(A-B) representative voltage clamp recordings of sEPSCs in NTS neurons 
from control mice. (C-D) Representative voltage clamp recordings of sEPSCs in 
NTS neurons from T1DM mice. (E) Cumulative fraction plot for the traces from A 
and B. (F) Cumulative fraction plot for the traces from C and D. (G) FGF19 does 
not alter sEPSC frequency in control mice (n = 14; p>0.05) but significantly 
increases sEPSC frequency in T1DM mice (n = 13; ***p<0.001). (H) FGF19 does 
not alter sEPSC amplitude in control mice (n= 14; p > 0.05) or in T1DM mice (n = 
13; p>0.05). Arrow indicates 2 s expanded portions indicated by the black bar 





4.3.4 FGF19 does not alter mEPSC frequency in NTS neurons from T1DM 
mice. 
 FGF19 increased mean spontaneous excitatory transmission in 
neurons from T1DM, but not normoglycemic mice, so further experiments were 
performed to understand the nature of this effect in T1DM mice only. To determine 
whether the effect on sEPSCs was due to actions at the soma or terminal of the 
presynaptic neuron, action potential independent, “miniature” excitatory 
postsynaptic currents (mEPSCs) were recorded (Fig 4.4). NTS neurons from 
T1DM mice were recorded similarly to the sEPSC recordings above with the 
addition of TTX (2 µM) to prevent action potentials. Unlike for sEPSCs, FGF19 
failed to alter mean mEPSC frequency in DMV neurons from T1DM mice (ACSF: 
2.60 ± 0.47 Hz; FGF19: 2.26 ± 0.60 Hz; n = 9; p > 0.05). FGF19 did not alter mean 
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mEPSCs amplitude (ACSF: 26.0 ± 4.34 pA; FGF19: 23.1 ± 3.64 pA; n = 9; p > 
0.05). These data, taken with the sEPSC results above suggest that FGF19 
consistently produced a net increase in synaptic excitability in the NTS of T1DM 
mice. Because this increase in sEPSC is abrogated in the presence of TTX, 






Figure 4.4. FGF19 does not alter mEPSC frequency in NTS neurons from 
T1DM mice.  
(A-B) representative voltage clamp recordings in NTS neurons from T1DM mice 
in the presence of TTX (2 µM). (C) FGF19 failed to alter mean mEPSC frequency 
(n = 9; p>0.05). (D) FGF19 failed to alter mean mEPSC amplitude (n = 9; 




4.3.5 FGF19 increases the excitability of glutamatergic AP neurons that 
project to the NTS in hyperglycemic mice. 
 Since FGF19 was found to increase the effect of glutamate 
photolysis in the AP and since the AP projects glutamatergic projections to both 
the NTS and DMV [68], it was determined that the AP was also a likely source of 
local excitatory input to the NTS. To identify the effects of FGF19 on glutamatergic 
neurotransmission from the AP to the NTS, glutamate uncaging was performed to 
increase activity of AP neurons while recording from neurons in the NTS (Fig 4.5). 
Because FGF19 was found to increase sEPSC frequency in NTS neurons from 
T1DM mice only, further glutamate uncaging experiments were restricted to this 
group of mice. When uncaging was performed in the AP, FGF19 significantly 
increased the mean effect of uncaging on EPSC frequency in the NTS (ACSF: 
4.34 ± 1.10 Hz; FGF19: 7.12 ± 0.98 Hz; n = 5; p < 0.05). Together, these data 
suggest that FGF19 increases the excitability of glutamatergic AP neurons that 





Figure 4.5. FGF19 increases the excitability of glutamatergic AP neurons that 
project to the NTS in hyperglycemic mice.  
(A) Representative voltage clamp recordings of evoked EPSCs for the AP to 
NTS circuit in T1DM mice. (B) Diagram showing a typical stimulation and 
recording location for cells in A and C. (C) Evoked EPSC response in this group 
before and after addition of FGF19 (n = 5; p<0.05). In representative traces, blue 
rectangle indicates stimulation time and duration. Arrows point to an expanded 





These results indicate that FGF19 increases glutamatergic transmission at 
multiple points in DVC circuitry in hyperglycemic, but not normoglycemic mice, 
with multiple implications regarding the understanding of FGF19 activity in the 
hindbrain. We found previously that FGF19 decreased blood glucose in 
hyperglycemic mice through actions in the dorsal hindbrain, and this effect was 
abrogated by co-administration of a peripheral muscarinic receptor blocker [51], 
suggesting a parasympathetic mechanism. Similar to the current findings, we also 
found that FGF19 altered the excitability of DMV neurons in a complex manner 
that was heavily influenced by hyperglycemic state. These results suggested that 
FGF19 functioned in the DVC through a relatively restricted mechanism – i.e., that 
FGF19 modified the activity of central vago-vagal reflexes, resulting in altered 
parasympathetic output. The current findings expand upon what was established 
previously by identifying multiple local, excitatory synaptic circuits within the DVC 
that are modulated by FGF19. These results are especially intriguing considering 
that, while the DMV is typically associated with autonomic regulation, the NTS and 
AP show extensive interconnectivity with several other brain regions [67, 68, 88, 
317-319]. This suggests that FGF19 in the hindbrain may regulate metabolism 
through multiple mechanisms in addition to autonomic changes, which is 
consistent with the diverse effects produced by ICV FGF19 reported previously 
[197, 198, 202, 203].  
Previous data showed that the effect of FGF19 on EPSC frequency in the 
DMV was blocked by TTX, suggesting a neuronal source that remained intact 
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within slice preparation. Although the source was unknown, it was hypothesized 
to be the NTS, since it is a primary source of synaptic input to the DMV and 
expresses the required receptors/co-receptor required to respond to FGF19  [277, 
278, 320, 321]. However, these same expression data suggested the intriguing 
hypothesis that the AP may also participate in the response of DMV neurons to 
FGF19. Indeed, the AP displays significantly higher expression of multiple FGFRs 
and ß-klotho than the NTS and shows some of the highest expression levels of 
any brain area [278]. Thus, neurons in the NTS and AP were tested regarding the 
effects of FGF19 on their glutamatergic connections to the DMV.  
The glutamate uncaging experiments performed here demonstrated that 
FGF19 increases the excitatory influence of both the AP and NTS on DMV 
neurons. The involvement of the NTS was predicted, since the excitatory NTS to 
DMV circuit has been well-characterized [21, 37, 54, 299]. However, there is 
vanishingly little known about the role of the AP in local vagal circuitry. 
Interestingly, there is evidence to suggest that the AP may be an unappreciated 
participant in the canonical vago-vagal reflex circuit. Several early tracing studies 
[322-325], later confirmed via viral and genetic techniques [68, 326], found that 
the AP receives afferent vagal sensory input and projects glutamatergic output 
toward the NTS and DMV. This suggests that the AP may serve as a vagal sensory 
integration center, in a similar capacity as the NTS. Despite this, there are little to 
no existing electrophysiological studies exploring the role that the AP plays in 
regulating local DVC circuitry.  
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The current findings confirm that AP neurons modulate DMV activity via 
glutamatergic synaptic connections and that FGF19 increases the activity of this 
input. This does not necessarily imply the existence of a monosynaptic connection, 
since it is possible that the AP regulates DMV excitability exclusively through 
intermediary NTS neurons. However, considering the widespread glutamatergic 
innervation from the AP throughout the DVC and the extensive dendritic fields of 
DMV neurons, it is likely that the AP communicates to the DMV both mono- and 
polysynaptically [55, 68]. A priori, in light of the AP’s traditional role as the principal 
emetic center in the brain, the existence of a monosynaptic connection from AP to 
DMV seems logical. This would allow direct and rapid control of gastric motility 
and stomach muscle contraction in response to noxious stimuli in the blood. 
Uncaging glutamate over a neuron causes a transient membrane 
depolarization that subsides over a period of ~500 ms. Consequently, an 
increased response to uncaging, as was seen here, is presumed to be the result 
an increase in excitability in the afferent neuron. Initial uncaging experiments 
indicated an increase in glutamatergic NTS neuron excitability in T1DM mice. To 
understand this, we first measured the intrinsic excitability of these neurons in both 
control and T1DM mice. The mouse model used here expresses EGFP in 
GABAergic neurons, so to increase the likelihood of patching from glutamatergic 
neurons, only EGFP-negative neurons were targeted for recording, though this 
does not guarantee that all neurons were glutamatergic. 
FGF19 produced a mixed effect on intrinsic excitability in these neurons, 
which did not appear to be dependent on hyperglycemic state. In both control and 
93 
 
T1DM groups, FGF19 failed to alter Rin and RMP in approximately half of NTS 
neurons. In the neurons that did respond, FGF19 tended to produce relatively 
subtle inhibitory effects, although a small proportion of neurons were excited by 
FGF19. Similarly, FGF19 produced a predominately inhibitory effect on evoked 
action potential firing in response to positive current injections. Often, large 
differences in evoked action potential response were also associated with effects 
on Rin and/or RMP, suggesting that the change action potential response was 
likely secondary to changes in membrane properties. These responses were 
mainly consistent with our previous findings in the DMV, which found moderate 
intrinsic inhibition in both control and T1DM groups in response to FGF19, 
suggesting that the peptide may interact with a common intracellular pathway 
downstream from the FGFR that is not modified by hyperglycemia [51]. 
The effects of FGF19 on NTS intrinsic excitability run contrary to the 
excitation that was predicted by glutamate uncaging. Although it is possible that 
the small proportion of NTS neurons that were excited by FGF19 was responsible 
for the increase in evoked EPSCs in T1DM mice, further experiments on synaptic 
excitability were warranted. FGF19 significantly increased sEPSC frequency in 
most NTS neurons from T1DM mice with no overall effect in control mice. This is 
consistent with the findings from Figure 4.1 and is likely a key driver of the FGF19-
induced increase in NTS to DMV excitatory transmission. Intriguingly, and in 
contrast to several other metabolic hormones, this effect was abolished with the 
addition of TTX, suggesting the involvement of intact upstream neurons [72, 327]. 
FGF19 was also found to moderately decrease sEPSC amplitude. This effect was 
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not reproduced in mEPSC recordings, indicating a presynaptic mechanism. This 
is likely explained by the concurrent increase in sEPSC frequency, suggesting that 
FGF19 may increase the frequency of smaller EPSC events, thereby decreasing 
mean EPSC amplitude. Since FGF19 was found to increase the activity of the AP 
to DMV glutamatergic connection, the effect of AP input to the NTS was tested. 
As hypothesized, FGF19 increased glutamate release in the NTS that was due to 
increased activity of AP neurons. One alternative explanation for the discrepancy 
seen here between intrinsic properties and glutamate uncaging is the involvement 
of calcium. FGFR activation has previously been shown to increase activity of the 
L-type calcium channel [328, 329]. EGTA was included in the intracellular solution 
used here, so any FGF19-induced changes in calcium dynamics in recorded NTS 
neurons were likely blunted or abrogated.  
Together, these data suggest that FGF19 increases glutamatergic 
neurotransmission at multiple points in the DVC circuit of T1DM mice. ICV 
administration of FGF19 decreases blood glucose concentration in T1DM but not 
control mice [51, 246, 296]. This suggests that the effects on blood glucose are 
likely to be determined by neurophysiological differences between control and 
T1DM groups. Although FGF19 produced intrinsic inhibition in some NTS 
neurons, this effect was broadly similar between both animal groups. Moreover, 
the effects on intrinsic excitability of NTS neurons does not appear to be 
consequential regarding their net excitatory influence on DMV neurons in T1DM 
mice. Rather, the more substantial effects of FGF19 on synaptic excitability in 
T1DM mice play a greater role in the peptide’s effect on vagal motor output. The 
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NTS phenotype observed here is also consistent with our previous results showing 
that FGF19 produced a moderate decrease in EPSC frequency in some DMV 
neurons from control mice [51]. 
In addition to neuronal input, the DVC regulates metabolism in response to 
humoral signals. The AP and NTS lack a fully functional blood-brain barrier due to 
local fenestrated capillaries, which allows the diffusion of humoral components 
into the DVC that might typically be excluded [56]. Additionally, NTS and DMV 
neurons have a wide dendritic field [55, 330] that can extend to the AP border. As 
such, it is likely that neurons in all three DVC nuclei can sense and respond to 
humoral signals. Neurons in the DVC have been shown to respond to many 
primary metabolic hormones [49, 50, 72, 79, 81, 86, 293]. Similar to the effects of 
FGF19 described here, leptin, insulin, CCK-8, and ghrelin modify glutamatergic, 
not GABAergic transmission in the DVC [49, 50, 72, 85, 327]. Despite this, 
GABAergic transmission is considered to be the primary determinant of DMV 
excitability during resting conditions since blockade of glutamatergic transmission 
in this area fails to produce effects on gastric motility or pancreatic secretion in 
normoglycemic mice [37, 54]. Interestingly, chemogenetic silencing of GABAergic 
NTS neurons fails to alter blood glucose concentration in normoglycemic mice, 
whereas increasing GABA neuron activity in the dorsal hindbrain increases blood 
glucose concentration [44]. This suggests that glucoregulatory DMV neurons may 
not show the same GABA-dominant phenotype seen with other DMV subgroups. 
The changes in cellular excitability in the DVC seen here are consistent 
with the beneficial metabolic effects associated with ICV administration of FGF19.  
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ICV FGF19 has been shown to decrease HGP [203] and hepatic expression of 
G6Pase, a key enzyme required for gluconeogenesis [198]. These effects can be 
replicated by injection of excitatory neurotransmitters into the DVC [48] or by 
increasing the excitability of DMV neurons as measured by c-fos staining [47]. 
Additionally, a common hallmark of FGFR activation is induction of 
phosphorylated extracellular signal-related kinase (pERK). Insulin activation of 
ERK signaling in the DVC is sufficient to decrease HGP, suggesting that FGF19 
may share this mechanism [293]. Furthermore, the increase in excitatory 
neurotransmission to the DMV seen here is consistent with a decrease in blood 
glucose concentration. Injection of NMDA in the DVC lowers HGP and this effect 
was prevented by a hepatic vagotomy, suggesting that the effect was mediated 
via the synaptic excitation of DMV neurons [48]. Additionally, increasing synaptic 
inhibition to the DMV increases blood glucose concentration [44]. Together, these 
results are consistent with a model in which increased excitatory input to the DMV 
produces a decrease in blood glucose concentration [331]. Accordingly, the 
effects of FGF19 seen here on DVC circuit dynamics are likely to produce 
beneficial effects on blood glucose levels in diabetic animals. 
The effects of FGF19 in the DVC found here may also modulate 
metabolism independently of autonomic mechanisms. Central delivery of FGF19 
has been shown to decrease food intake, which could be explained via alterations 
in DVC excitability [197, 202]. Similar to the effects of insulin on HGP, satiation 
produced by CCK in the DVC requires induction of pERK, suggesting that FGF19 
may decrease food intake via a shared mechanism. The NTS and AP also exhibit 
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significant connections to other nuclei associated with regulation of ingestive 
behavior including the lateral parabrachial nucleus (PBN) [68, 332] and the 
hypothalamus [333]. The experiments performed here focus on local circuitry 
within the DVC. As such, it is not known whether connections to other nuclei such 
as the PBN or hypothalamus are altered by FGF19. However, considering the 
significant expression of FGFR/β-Klotho throughout the NTS and AP, it is likely 
that FGF19 alters the activity of neurons that project distally as well as those that 
participate in local vago-vagal reflexes [277, 278]. 
The DVC is a key metabolic regulatory area of the brain. Although the DVC 
is typically associated with autonomic regulation of metabolism, the AP and NTS 
also serve as a communication hub between the DVC and several other key 
nuclei. Alterations in DVC excitability, such as those seen here, are likely to 
produce profound effects on multiple aspects of metabolism. Consistent with our 
previous work, these data suggest that FGF19 alters parasympathetic output in 
T1DM mice by increasing synaptic excitability of DMV neurons. Interestingly, our 
findings demonstrate a role for the AP in the direct regulation of the vago-vagal 
reflex mechanism and that this connection can be modified by a metabolic 
hormone. Though not confirmed, it is possible that other metabolic hormones work 
similarly in this area. Overall, the electrophysiological effects seen here are 
consistent with the beneficial metabolic effects of ICV FGF19. Although these 
findings implicate a primarily autonomic mechanism, FGF19 was also found to 
significantly alter AP and NTS excitability. This raises the possibility that FGF19 
may interact with the DVC to produce an array of beneficial metabolic effects 
through alteration of vagal parasympathetic output and through regulation of 




5 General Discussion 
5.1 Review of Major Findings 
It was previously established through the work of several research groups 
that FGF19 produces powerful antidiabetic effects when administered to the brain 
[186, 197, 198, 202, 203]. Excluding Fu et al., all of these papers either explicitly 
or implicitly explored a hypothalamic site of action for ICV FGF19. This report is 
the first to identify the effects of FGF19 in the DVC. Chapter 3 of this dissertation 
first established that administration of FGF19 to the hindbrain was sufficient to 
significantly decrease blood glucose concentrations in T1DM mice. Similar to 
previous reports on ICV FGFs, this effect only occurred in hyperglycemic mice and 
did not produce hyperglycemia [246]. This effect was abrogated by co-
administration of MSA, a peripheral muscarinic receptor blocker. Although not fully 
confirmative, this suggests that FGF19 decreased blood glucose by acting through 
the vagus nerve. 
Chapter 3 also established several electrophysiological effects of FGF19 
on DMV neurons. Since the in vivo data indicated a likely change in vagal 
parasympathetic output, the effect of FGF19 on DMV neurons was measured. 
FGF19 produced several effects that differed as a function of disease state (i.e. 
presence of hyperglycemia). In the DMV, FGF19 moderately decreased glutamate 
release from control mice and consistently increased glutamate release in T1DM 
mice. This effect was prevented with the addition of TTX, a Nav/action potential 
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blocker, suggesting that FGF19 increased the activity of glutamatergic neurons 
immediately afferent to the DMV.  
FGF19 produced mixed effects on the intrinsic excitability of DMV neurons. 
Quantitatively, FGF19 decreased the input resistance of neurons from T1DM mice 
and decreased the RMP of neurons from control mice. However, on an individual 
neuron level, FGF19 produced generally inhibitory effects on both measures from 
both sets of neurons. This suggests that hyperglycemia does not modify the 
intracellular process that produces these effects. Consistent with these data, 
FGF19 produced mixed effects on action potential (IAP) frequency of DMV 
neurons. In control mice, FGF19 produced no change, an increase, or a decrease 
in IAP frequency in approximately equal amounts while in T1DM mice, FGF19 
decreased IAP frequency in most neurons with an increase in one neuron.  
Finally, FGF19 decreased A-type potassium channel (KA) current amplitude 
in control mice only. First, it was found that FGF19 decreased the amplitude of the 
initial peak current elicited by voltage activation steps in control mice only. This 
effect was blocked in the presence of 4-AP, a KA channel blocker, and when the 
internal solution contained Cs+, a K+ channel blocker, as the primary cationic 
charge carrier.  Since the current was blocked by 4-AP and by Cs+, it was 
determined to be KA. Altogether, the data from Chapter 3 indicate that FGF19 
decreases blood glucose, likely by altering DMV neuron excitability. In vitro studies 
revealed that FGF19 produced a complex phenotype of electrophysiological 
responses in the DMV and that this phenotype was heavily modified by the 
presence of hyperglycemia.  
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Chapter 4 of this dissertation explored the effects of FGF19 on neurons 
upstream to the DMV. Since FGF19 decreased blood glucose in T1DM mice only 
in Chapter 3, it was hypothesized that the most important electrophysiological 
responses must be the ones that occurred in T1DM mice and not in control mice. 
This suggested that the increased IAP-dependent glutamate release in the DMV 
was the most likely driver of the beneficial effects on blood glucose. To explore 
this, Chapter 4 focused entirely on electrophysiology and these experiments were 
aimed at identifying the involvement of the NTS and AP in the FGF19-mediated 
increase in DMV glutamate. First, glutamate photolysis experiments were 
performed. Briefly, DMV neurons were recorded while caged glutamate was 
photoactivated in either the NTS or the AP. In control animals, FGF19 did not 
affect glutamate uncaging in the NTS. This was consistent with the results from 
Chapter 3. In T1DM animals, FGF19 increased glutamate release in the DMV 
when photoactivation was performed in either the AP or the NTS. These results 
confirmed the hypothesis that FGF19 increased the activity of glutamatergic 
neurons in the AP and NTS, leading to increased glutamate in the DMV. No 
experiments were performed to understand if the connection from AP to DMV was 
monosynaptic or if the NTS served as an intermediary. 
Next, the effects of FGF19 in the NTS were explored. FGF19 produced 
unexpected effects on NTS intrinsic excitability. In both control and T1DM groups, 
FGF19 produced mixed effects on excitability with a definite trend towards 
inhibition. Rin was decreased in RMP was hyperpolarized in approximately half the 
cells of both groups. The remainder of cells tended to either show no change with 
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a small subset of cells showing excitatory effects. Considering the consistent 
responses seen in the glutamate uncaging experiments, these results ran 
somewhat contrary to what was expected. It is possible that the small number of 
neurons that were excited by FGF19 could be responsible for the increased 
glutamate release in the DMV but we hypothesized that the observed excitatory 
effects would likely be found in synaptic measurements. This hypothesis was 
indeed borne out. FGF19 increased EPSC frequency in the NTS in most cells from 
T1DM mice with no effect on mean EPSC frequency in control mice. This result 
was consistent with the previous findings from Chapter 3 and Figure 4.1. Further 
EPSC recordings were made in T1DM mice with the addition of TTX to block 
action potentials. The addition of TTX blocked the excitatory effect of FGF19 in 
the NTS, suggesting that the source of glutamate was from cells left intact in slice 
preparation and not, for example, glutamate terminals from vagal afferents. 
Finally, to confirm the source of this input, glutamate photolysis experiments were 
performed in the AP while recording in the NTS. It was found that FGF19 
increased the activity of glutamatergic AP neurons that project to the NTS. The 
implications of these results and their roles within the larger context of CNS control 
of blood glucose will be discussed in detail below. 
5.2 Effects of Central Delivery of FGF19 on Blood Glucose 
5.2.1 Previous Findings 
In Chapter 3, it was found that hindbrain application of FGF19 produced a 
significant decrease in blood glucose concentrations in T1DM mice only. This 
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effect was found to be dependent on peripheral muscarinic receptor signaling. 
However, no further experimentation was performed to understand the target 
tissue or mechanism. Therefore, it is unknown if the decrease in blood glucose 
was, for example, caused by a decrease in HGP, an increase in glucose disposal, 
or if hormones such as glucagon were involved.  
Despite the lack of mechanistic details, certain parallels can be drawn with 
other studies that may give clues to the likely mechanism here. First, due to the 
use of a T1DM model, it can at least be safely assumed that insulin was not 
responsible here. This is consistent with previous studies on CNS FGF19. Morton 
et al. found that ICV FGF19 decreased blood glucose likely through increased 
metabolism of glucose to lactate and that there was no change in insulin secretion 
[198]. Ryan et al. found that insulin levels did not differ between ICV vehicle and 
ICV FGF19 groups at multiple time points after injection [197]. However, the latest 
time point for insulin measurements in this study was only 15 minutes, meaning 
that there could be a change in insulin at a later time point.  
Perry et al. found that ICV FGF19 decreased blood glucose in T1DM rats 
with no changes in insulin levels between the groups [203]. At first glance, due to 
the similarities in models used, it could be assumed that this paper may be the 
closest to explaining the mechanism for FGF19 in the hindbrain. However, the 
authors determined that the decrease in blood glucose was the result of altered 
hypothalamic-pituitary-adrenal axis changes leading to decreased corticosterone. 
Thus, since in Chapter 3 it was found that the effect on blood glucose was 
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dependent on peripheral muscarinic receptor signaling, it is unlikely that the 
mechanism is shared.  
Intriguingly, the results in Marcelin et al. run somewhat contrary to the three 
other studies and indeed indicate a change in insulin signaling [202]. This may be 
due to a difference in methodology since this study performed four daily ICV 
injections of FGF19 instead of a single injection. This study found that in ob/ob 
and HFD mice, FGF19 decreased fasting insulin levels, indicating an increase in 
insulin sensitivity. It was also found that, in the FGF19 groups, insulin secretion 
was increased in response to a glucose challenge, where in vehicle-injected 
groups it did not. This suggests that chronic FGF19 administration may produce 
additional effects on glucose-induced insulin secretion and insulin sensitivity as 
compared to acute injection.  
5.2.2 The DVC and Blood Glucose 
Since the experiments here involved acute administration of FGF19 and 
were dependent on peripheral muscarinic receptor engagement, the most likely 
mechanism involves vagus nerve-mediated effects on peripheral organs. 
Peripheral blockade of muscarinic receptors can be used as an indirect and less 
invasive alternative to a surgical procedure such as a vagotomy. Briefly, the DMV 
consists of preganglionic motor neurons that communicate to postganglionic 
neurons in the periphery through acetylcholine activation of nicotinic receptors 
[334, 335]. In turn, the peripheral postganglionic neurons exert their effects 
primarily through acetylcholine activation of muscarinic receptors on target tissues 
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[12, Chapter 31]. Although the DMV projects to most visceral tissues, the most 
likely target tissues for the effects seen here are either the liver or the pancreas. 
5.2.2.1 DVC Regulation of the Pancreas 
Pancreatic exocrine and endocrine release is heavily regulated through 
vagal cholinergic innervation. It is well known that the DMV regulates pancreatic 
exocrine secretions through a peripheral muscarinic receptor-dependent 
mechanism [43, 311]. Pancreatic exocrine secretions are vital for proper nutrient 
processing and loss of pancreatic exocrine function results in poor nutrient 
absorption and malnutrition. [336]. However, it is unlikely that ICV FGF19 works 
through this mechanism as it works through the activation of muscarinic receptors. 
Activating muscarinic receptors increases pancreatic exocrine secretions, leading 
to better nutrient absorption and likely higher blood glucose levels. 
Pancreatic endocrine release is also under the control of peripheral 
muscarinic receptors. Unilateral electrical stimulation of the DMV increases 
plasma insulin levels by 100%-200% and this effect was blocked with a muscarinic 
blockade or vagotomy [41]. Bilateral electrical stimulation of the lateral DMV 
results in increased insulin and glucagon secretion [337]. Chemical disinhibition of 
the DMV also produces an increase in pancreatic insulin release [42]. The animals 
used here are a model of T1DM, and as such, have little to no ß-cells remaining. 
This suggests that increased insulin release is not involved.  
Efferent projections from the DMV also regulate pancreatic glucagon 
secretion [337]. Acetylcholine release from efferent vagal terminals can stimulate 
glucagon release [337-340] and disruption of pancreatic M3 muscarinic receptor 
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signaling prevents acetylcholine-stimulated glucagon secretion [341]. Glucagon is 
traditionally thought of as a counterregulatory hormone, released from pancreatic 
α-cells, that increases blood glucose in response to hypoglycemia [342]. Both 
T1DM and T2DM are associated with hyperglucagonemia, leading to increased 
fasting blood glucose [343, 344]. Glucagon receptors are located primarily in the 
liver and kidney but are also found in the brain, heart, adipocytes, pancreas, and 
many other tissues [345]. Glucagon has many actions but the most relevant of 
these is regards HGP. Glucagon promotes glycogenolysis and gluconeogenesis 
while suppressing glycolysis and glycogenesis [346]. The resulting phenotype is 
one of greatly increased hepatic glucose release with a concurrent decrease in 
hepatic glucose breakdown and storage. However, it is again unlikely that 
hindbrain administration of FGF19 decreases glucagon release. The effects seen 
here rely on peripheral muscarinic receptor activation, which would be expected 
to increase glucagon levels. 
5.2.2.2 DVC Regulation of the Liver 
The most likely mechanism to explain the effects of hindbrain FGF19 on 
blood glucose is direct vagal modulation of hepatic glucose metabolism. In 
contrast to the effects seen in the pancreas, increasing the activity of vagal outputs 
to the liver results in a decrease in blood glucose. As noted elsewhere, the 
activation of neurons in the DVC leads to a decrease in HGP. Injection of NMDA, 
an excitatory neurotransmitter, into the DVC decreases HGP by ~50%, an effect 
that is blocked by a vagotomy [48]. Another study found similar results, where 
central regulation of HGP relied on the activation of DMV neurons and required an 
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intact hepatic branch of the vagus nerve [47]. Perfusion of isolated rat liver with 
acetylcholine causes an increase in glucose production and glycogen content, an 
effect that was abrogated by atropine, a muscarinic receptor antagonist [347]. This 
study also found that hepatocytes express M3 muscarinic receptors. 
It is not fully known how vagal output produces its effects on hepatic 
glucose metabolism. There are no identified hepatic postganglionic neurons, 
suggesting a direct connection from the DMV to the liver [348]. Anterograde 
tracing studies from the DMV show no labeling in the hepatic parenchyma or in 
vagal nerves or paraganglia [46]. There was labeling found associated with bile 
ducts and portal vessels. Moreover, the vagal efferent markers 
acetylcholinesterase is not found in the liver parenchyma of humans or any other 
species surveyed [349-355]. Regardless, activation of DMV neurons leads to a 
vagus nerve hepatic branch-dependent suppression of HGP that was likely 
caused by decreases in glucose metabolism enzymes [47]. Importantly, during 
this experiment, hepatic glucose dynamics were measured under pancreatic 
clamp conditions to prevent changes in glucagon and insulin levels. Thus, it is 
likely that neurons in the DMV can act directly on the liver to regulate glucose 
metabolism. Although not confirmed, this is the most likely mechanism to explain 
the antidiabetic effects of FGF19 in the hindbrain. 
5.2.2.3 Potential Involvement of Other Organs 
The DMV projects to many organ systems so it is possible FGF19 could 
work through these tissues though it is unlikely. One alternative possibility to 
explain the hepatic branch-dependent actions outlined above in Pocai et al. [47] 
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is that the DMV may act indirectly through another organ system that is innervated 
by the hepatic branch of the vagus. This branch innervates not only the liver, but 
also the duodenum with additional sparse labeling in the stomach, jejunum, ileum, 
cecum, and colon [29, 46]. It is not known whether the results in Chapter 3 are 
dependent on the hepatic vagus and therefore could work through any organ that 
the DMV projects to, including the heart, lungs, stomach, esophagus, small 
intestine, and colon [12, 29, 356, 357]. It is not immediately clear how vagal actions 
within these organs might decrease blood glucose for 12 hours although the 
possibility of such a mechanism cannot be discounted. A theoretical mechanism 
might include vagal stimulation of hormone release from one of these organs or 
possible changes in gastric motility or nutrient absorption. 
5.2.3 Involvement of the Hypothalamus 
Excluding Fu et al, all of the primary studies on ICV FGF19 focused on the 
hypothalamus. The evidence for hypothalamic sites of action varied. Ryan et al. 
only quantified hypothalamic FGFR expression and made no other inferences to 
hypothalamic function [197]. Morton et al. looked for co-localization of c-fos 
expression with POMC neurons and found that FGF19 activated non-POMC 
positive hypothalamic neurons [198]. Marcelin et al. further established that 
FGF19 suppressed hypothalamic AgRP/NPY neurons and that this effect relied 
on central ERK signaling [202]. Finally, Perry et al. found that ICV FGF19 
decreased ACTH and corticosterone levels, implying a hypothalamic-pituitary 
mechanism [203]. Overall, this evidence is convincing that FGF19 does work in 
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the hypothalamus. However, it is possible that some of the effects in the 
hypothalamus still work by activating DVC neurons. As mentioned elsewhere, 
hypothalamic regulation of HGP seems to require the activation of DVC neurons 
and an intact vagus nerve [47, 92]. However, it is unknown if the same circuit is 
required for the changes in hepatic metabolism in glucose to lactate as was seen 
in Morton et al. [198]. 
It is also known that ICV FGF19 modulates the activity of a hypothalamic 
to DVC glucoregulatory circuit. Neuroglucopenia (CNS shortage of glucose) 
increases DVC neuron and vagus nerve activity, leading to increased glucagon 
secretion. Interestingly, ICV FGF19 dampens these effects, effectively 
dysregulating a physiological counterregulatory response to hypoglycemia [295]. 
One possible explanation for this phenomenon is that, in a physiological context, 
FGF19 is a gut signal that indicates a high energy balance. FGF19 is released 
within a few hours after eating and can be thought of in many ways as a late-acting 
hormone similar to insulin [358]. In this capacity, FGF19 may prevent inappropriate 
glucagon release by signaling to the brain to desensitize a hypothalamus-DVC-
pancreas circuit that is activated by hypoglycemia. Interestingly, there are neurons 
within the NTS that are activated by hypoglycemia and regulate glucagon 
secretion through connections to the DMV [71]. In light of the widespread inhibitory 
effects on NTS intrinsic excitability found in Chapter 4, FGF19 might also function 
to inhibit this circuit as well. 
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5.3 The Cellular Effects of FGF19 in the DVC: Implications for Metabolism 
When injected into the hindbrain, FGF19 decreased blood glucose in a 
peripheral muscarinic receptor-dependent manner. As outlined in Chapter 5.2.2, 
this is heavily suggestive that FGF19 exerts its effects via the vagus nerve. DMV 
neurons can regulate blood glucose concentrations and were shown to respond 
to FGF19 in Chapters 3 and 4. Therefore, the overarching hypothesis of this 
dissertation is that FGF19 modulates the excitability of neurons in the DVC that 
ultimately leads to altered activity of DMV neurons and thus, altered 
parasympathetic vagal output. Within this framework, the primary focus is DMV 
excitability, with all other effects being secondary contributors to DMV function. 
More specifically, since FGF19 in the hindbrain improved glycemia in T1DM mice 
only, the hypothesis proposed above holds that the FGF19-induced changes in 
the excitability of DMV neurons from T1DM mice must explain the observed 
changes in blood glucose concentrations.  
Multiple models exist that may explain how FGF19 in the DVC might alter 
DMV activity to lower blood glucose. The first model makes the assumption that 
the in vitro conditions seen during electrophysiology experiments are a somewhat 
faithful reflection of the state of the DVC in an intact animal. In Chapters 3 and 4, 
it was found that FGF19 significantly increased synaptic excitability to the DMV 
while simultaneously causing a decrease in intrinsic excitability. This led to a 
decrease in IAP frequency in 7/8 neurons and a decrease in 1/8. All previous data 
suggests that an increase in DMV activity is required for a liver-mediated decrease 
in blood glucose [47, 48]. This hypothesis also supported by the MSA experiment 
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in Chapter 3, since blockade of muscarinic activity prevented FGF19 from lowering 
blood glucose. It is entirely possible that the 1/8 DMV neurons that was acutely 
excited by FGF19 could be responsible for the metabolic changes. The hepatic 
branch DMV neurons consist of a small number of neurons on the left side of the 
DVC only and the DMV neurons in Chapter 3 were not identified by their target 
organ [26]. This model would imply that the organization of synaptic inputs and 
receptor expression of hepatic-projecting DMV neurons is such that the intrinsic 
inhibitory effects of FGF19 were minimized and the excitatory synaptic effects 
were maximized. To confirm this, future studies should include retrograde labeling 
so that DMV neurons that project to different organs can be compared regarding 
their responsiveness to FGF19. 
The second model is one in which the electrophysiological recording 
circumstances in Chapters 3 and 4 are too far removed from intact animal 
physiology and are thus missing one or more key components that change how 
FGF19 works in the DVC. Potential confounding factors include unaccounted for 
effects on plasticity, the removal of synaptic inputs, and mismatch of the 
components in the ACSF with what is in the brain. First, there is a time mismatch 
between the in vitro and in vivo effects. In vitro effects were measured acutely, 
after five minutes of FGF19 application while in vivo effects were first measured 
at 6 hours after injection. It is possible that changes in synaptic plasticity occurred 
during this interval. This hypothesis is supported by the fact that multiple FGFs 
enhance long-term potentiation and paired pulse facilitation in the hippocampus 
after 10-20 min of application [359, 360].  
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Second, slice preparation like what is performed in the experiments in this 
work inherently remove a large proportion of the synaptic inputs to a given 
nucleus. Although an exact number is not known for the DVC, it was found in the 
hippocampus that neurons in slice preparation received approximately 4.5 fold 
fewer EPSCs when compared to in vivo recordings [361]. If this same relationship 
holds true in the DMV, then the consistent FGF19-induced increase in sEPSC 
frequency of T1DM would have an outsized influence and would be much more 
likely to overcome any intrinsic inhibitory effects. Slice preparation also removes 
input to the DVC from distal areas including vagal afferents and the hypothalamus. 
It is possible that the inclusion of input from these sources might alter how FGF19 
works in the DVC. Additionally, FGF19 altered the excitability of the AP and NTS 
T1DM mice. Since both the AP and NTS project to the hypothalamus, it is possible 
that FGF19 could activate a reciprocal DVC –hypothalamus-DVC connection that 
modulates DMV activity in an important way [67, 89, 90]. 
Finally, FGF19 in the hindbrain may rely on high glucose concentrations or 
other hormones to produce its effect. The mice in the in vivo experiments were 
severely hyperglycemic (typically 500-600 mg/dL) but the ACSF used for in vitro 
experiments was much lower (198 mg/dL). It is not known what glucose 
concentration the DVC sees but it is possible that neurons in the DVC of diabetic 
mice experience higher glucose levels than what is found in ACSF. Since a primary 
effect of FGFs is the stimulation of glucose uptake, it is possible that higher 
ambient glucose levels may produce a greater response [286]. FGF19 may also 
synergize with other hormones in the DVC. The DVC responds to leptin [49, 72-
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74], glucagon [79], GLP-1 [64, 80-84], and ghrelin [85-87] among others. The 
physiological action of one or more of these hormones may be required for FGF19 
to exert its effects.  
FGF19 may also require the actions of specific hormones that act on cAMP. 
It is known that drug modulation of inhibitory neurotransmission in the DMV often 
can only occur when cAMP levels are elevated. Opioids and the pancreatic 
polypeptides NPY and PYY fail to alter IPSCs in the DMV under resting conditions 
but an effect is revealed when cAMP levels are increased via forskolin, TRH, CCK-
8s, or vagal deafferentiation [313, 362-366]. It was found that increasing cAMP 
levels alters receptor trafficking at the presynaptic terminal, allowing opioids, NPY, 
and PYY to act there to regulate GABA release. This system also is involved in 
insulin signaling in the DVC and is dysregulated by diabetes (discussed in Chapter 
5.4.1). The DVC participates in endogenous TRH and CCK signaling [367, 368], 
and cAMP regulates FGFR trafficking in some tissues [369, 370]. It is not known 
whether cAMP contributes to the FGF response in the DVC but this topic could 
prove to be valuable for future research. 
5.4 The Effects of Diabetes on the Brain 
Many of the cellular effects seen in Chapters 3 and 4 were heavily modified 
by hyperglycemia. In Chapter 3, FGF19 caused a moderate decrease in sEPSC 
frequency in some neurons from control mice and a significant increase in sEPSC 
frequency in all neurons from T1DM mice. Also in Chapter 3, FGF19 decreased 
the amplitude of A-type K+ currents in control mice only with no effects in T1DM 
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mice. Similarly, in Chapter 4, FGF19 increased glutamatergic neurotransmission 
from the NTS to the DMV in T1DM mice only. The underlying mechanism that is 
modified by hyperglycemia is unknown. However, there are numerous 
documented changes in DVC excitability and neurotransmission that occur in 
response to high blood glucose concentrations. Additionally, hyperglycemia 
modifies many of the intracellular signaling pathways that are activated by FGFRs. 
These changes will be outlined here with the goal of providing a background as to 
why FGF19 might affect neurons from diabetic mice differently. 
5.4.1 The Effect of Diabetes on the DVC 
First, past studies from this lab and others have shown that even a short 
history of hyperglycemia can lead to dramatic changes in DVC neuron excitability. 
Hyperglycemia causes a significant increase in EPSC frequency in the DMV [51, 
282, 284]. The nature of this effect is not fully understood but it likely represents a 
compensatory response to hyperglycemia. Since most indications suggest that 
increasing DMV neuron activity suppresses blood glucose, an increase in synaptic 
excitability would likely be beneficial in a hyperglycemic context [44, 47, 48].  
Diabetes also interferes with DVC neuron response to insulin. As discussed 
in Chapter 5.3, drug modulation of inhibitory transmission in the DVC is often only 
achievable if cAMP levels are elevated. In control mice, insulin can modulate 
GABA release in the DMV only when elevated cAMP levels are elevated by 
forskolin [77]. This effect was found to rely on Golgi protein trafficking and glucose 
transport. Interestingly, insulin was unable to modulate GABA release in the DMV 
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in diabetic mice, even in conditions of increased cAMP. Drawing parallels with 
previous studies, this suggests that cAMP levels regulate insulin receptor 
trafficking on GABA terminals presynaptic to the DMV and that hyperglycemia 
disrupts this response. 
Diabetes also alters several other aspects of DVC excitability. 
Hyperglycemia increases the DMV response to GABA by increasing the 
proportion of GABA receptors that express the δ-subunit, likely via a 
posttranslational mechanism [283]. Similarly, diabetes also altered GABA 
responsiveness in the DMV by increasing transcription of GABA receptors 
containing the α1 and γ subunits [285]. It was also found that diabetes increases 
glutamate release to DVC GABA neurons that project to the DMV, ultimately 
leading to increased GABAergic activity to the DMV [281]. Finally, hyperglycemia 
impairs neuronal glucose sensation in the DVC. The glucose sensing response of 
NTS neurons involves glucokinase, an enzyme that converts glucose to glucose-
6-phosphate. Diabetes decreases glucokinase expression in the DVC, leading to 
impaired electrophysiological responsiveness to changing extracellular glucose 
concentrations [280]. 
5.4.2 The Effect of Diabetes on FGFR Signaling Pathways 
Diabetic hyperglycemia also is known to dysregulate several of the 
intracellular pathways that are activated by FGFRs. FGFRs signal through MAP 
kinases, PLCγ, and PI3K/Akt (see Chapter 1.3.5). It has been suggested that MAP 
kinases such as JNK, p38, and ERK mediate damaging effects of high glucose 
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concentrations. Diabetes causes oxidative stress in neurons through the depletion 
of NADPH, thereby interfering with the antioxidant defense mechanism [303]. 
Moreover, insulin resistance is positively correlated with oxidative damage in the 
brain [371]. In rat sensory neurons, high glucose activates JNK and p38 and 
oxidative stress activates p38 and ERK leading to damage of these cells [302]. In 
the dorsal root ganglia, experimentally induced diabetes causes sustained 
activation of all three groups of MAP kinases [302]. In this study, inhibition of p38 
or ERK prevented the damage caused by oxidative stress, suggesting that these 
kinases serve as neuronal damage transducers in diabetes. 
There is abundant evidence that diabetes interferes with the PLCγ pathway 
throughout the periphery but less is known about what occurs centrally [304, 372]. 
Both hyperglycemia and FGFR signaling activate PLC [303]. Activation of PLCγ 
hydrolyzes PIP2 into IP3, which releases Ca2+ from the ER, and DAG, which 
activates PKC. Importantly, PKC increases MAP kinase expression and promotes 
oxidative damage by acting on NADPH-oxidase [303]. It is well known that 
diabetes increases total DAG or do novo synthesis of DAG in vascular tissues, the 
heart, liver, and skeletal muscle [304, 372]. In nerve tissue, DAG is decreased by 
hyperglycemia although little is known about the effects of diabetes on DAG in the 
brain [373, 374]. Despite this, it is known that T1DM regulates brain expression 
patterns of various isoforms of PKC, the next downstream molecule from DAG 
[375, 376]. It is unknown what function this PKC reorganization plays but it may 
contribute to impairment of neurovascular coupling and modulation of multiple K+ 
channels [376, 377]. 
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Diabetes also interferes with the PI3K-Akt system. PI3K is one of the 
primary downstream signaling pathways of insulin and is dysregulated in many 
tissues following insulin resistance or loss of insulin signaling [378]. PI3K/Akt 
signaling is dysregulated in the vagus nerve of diabetic rats and may contribute to 
diabetic autonomic neuropathy [379, 380]. Moreover, diabetes decreases levels 
of phosphorylated PI3K and Akt in the brain, indicating a disruption in signaling 
[305]. It is likely that these alterations in PI3K/Akt signaling are detrimental, not 
compensatory, since CNS upregulation of PI3K leads to improvements in 
glycemia and hypothalamic-pituitary-adrenal axis activity [381]. 
It is unknown whether these same dysregulations occur within the DVC. 
However, considering the wide range of intracellular signaling defects induced by 
hyperglycemia throughout the body, it is unlikely that the DVC is immune to these 
phenomena. Glucose levels in the brain are typically tightly regulated. However, 
due to the local leaky blood brain barrier, it is likely that neurons in the DVC are 
subjected to high sustained glucose concentrations similar to what is experienced 
by cells in the periphery. Thus, it is possible that neurons in the DVC may have 
more in common with peripheral cells regarding their intracellular signaling milieu 
than with CNS neurons that lie inside the blood brain barrier.  
5.5 Final Conclusions 
Together, these data show that FGF19 decreases blood glucose when 
administered to the hindbrain and alters excitability in the DVC in several distinct 
and often opposing ways. Many of the effects seen here differed according to 
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disease state and were occasionally inconsistent even within the same cell types 
in the same animal. This is unsurprising, as none of the three nuclei contained 
within the DVC can be considered monolithic. It is well documented that neurons 
in the three DVC nuclei can be heavily subdivided based on receptor expression, 
response to glucose, target organ, and other criteria. However, throughout the 
findings in both Chapter 3 and Chapter 4, FGF19 consistently increased 
glutamatergic transmission in T1DM mice. This effect occurred in most neurons 
surveyed in both the NTS and DMV. This suggests that, despite the wide 
differences found between neurons in this area, FGF19 seemed to activate a 
mechanism that is both highly conserved and able to be modified by 
hyperglycemia. Moreover, prior studies support a model in which an increase in 
synaptic glutamate activity in the DVC leads to decreased blood glucose levels. 
Further research in this area should focus on identifying the particular mechanism 
responsible for increased glutamate release in the DVC so that it can be 
harnessed and understood. 
 The experiments outlined in this work are novel in several ways. First, there 
are no other published studies looking at administration of FGF19 to the hindbrain. 
Moreover, there is only one other study looking at FGF19 administration to T1DM 
mice. Next, there are no extant studies identifying the electrophysiological effects 
of FGF19. There are a small number of papers that performed electrophysiology 
with other FGFs but these mostly focused on calcium. Finally, there are vanishingly 
few papers that have explored the role of the AP in local DVC signaling. While 
there are studies that show the AP projects extensively throughout the NTS and 
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DMV, there are very few, if any, papers that have established that the AP can 
modulate activity in the DMV. This implies that the AP may participate in the vago-
vagal reflex and warrants extensive future study. Due to their novelty, the papers 
contained in this dissertation cannot be considered the definitive work on the 
subject. These papers contain many novel findings but do not fully explore their 
underlying mechanisms or their relevance to metabolic regulation. Instead, this 
work should serve as the first step in a long line of research that may lead to better 
patient outcomes or at least a better understanding of how the brain can be 
harnessed to improve metabolism. 
Appendices 
Abbreviations 
µg ......................................................................................................... Micrograms 
4-AP ............................................................................................... 4-aminopyridine 
4V .................................................................................... Fourth cerebroventricular 
ACSF ............................................................................ Artificial cerebrospinal fluid 
AgRP .................................................................................... Agouti-related peptide 
Akt ................................................................................................. Protein kinase B 
AMPA ................................ α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ANOVA.................................................................................... Analysis of variance 
AP .................................................................................................... Area postrema 
AP ................................................................................................... Action potential 
ATP .................................................................................... Adenosine triphosphate 
AUC ....................................................................................... Area under the curve 
BAT ....................................................................................... Brown adipose tissue 
CA ........................................................................................................... Citric acid 
CCK ............................................................................................... Cholecystokinin 
CNS ................................................................................... Central nervous system 
CYP7A1 ....................................................................... Cholesterol 7α-hydroxylase 
DAG .................................................................................................. Diacylglycerol 
DIO ........................................................................................ Diet-induced obsesity 
DMV .................................................................. Dorsal motor nucleus of the vagus 
DVC ...................................................................................... Dorsal vagal complex 
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FGFR ................................................................... Fibroblast growth factor receptor 
FXR ........................................................................................ Farnesoid X receptor 
GABA ........................................................................... Gamma-amino butyric acid 
GFP ................................................................................. Green fluorescent protein 
GI ................................................................................................... Gastrointestinal 
GLP-1 ................................................................................ Glucagon-like peptide-1 
HEPES .................................... 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HFD ...................................................................................................... High-fat diet 
HGP ............................................................................. Hepatic glucose production 
Hr ................................................................................................................... Hours 
HS  .................................................................................................. Heparin sulfate 
HSPG ......................................................................... Heparin sulfate proteoglycan 
Hz .................................................................................................................... Hertz 
IAP ..................................................... Spontaneous sodium action potential current 
ICV ...................................................................................... Intracerebroventricular 
iFGF .................................................................Intracellular fibroblast growth factor 
IP3 ........................................................................................... Inositol triphosphate 
IPSC ....................................................................... Inhibitory post-synaptic current 
K-S ............................................................... Kolmogorov-Smirnov two sample test 
KYN .................................................................................................. Kynurenic acid 
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MAP ..................................................................... Mitogen-activated protein kinase 
mEPSC .................................................. Miniature excitatory post-synaptic current 
min .............................................................................................................. Minutes 
MNI-caged glutamate ...................... 4-Methoxy-7-nitroindolinyl-caged-L-glutamate 
ms ........................................................................................................ Milliseconds 
MSA .................................... (-)-scopolamine methyl bromide (methylscopolamine) 
mV .............................................................................................................. Millivolts 
MΩ ........................................................................................................ Megaohms 
NADPH............................................ Nicotinamide adenine dinucleotide phosphate 
Nav ................................................................... Voltage-activated sodium channels 
NMDA............................................................................... N-methyl-D-aspartic acid 
NPY ................................................................................................ Neuropeptide Y 
NTS ................................................................................. Nucleus tractus solitarius 
pA ............................................................................................................ Picoamps 
PBS ............................................................................... Phosphate-buffered saline 
PCR .............................................................................. Polymerase chain reaction 
pERK ........................................ Phosphorylated extracellular signal-related kinase 
PI3K .............................................................................. Phosphoinositide 3-kinase 
PIP2 ............................................................. Phosphatidylinositol 4,5-bisphosphate 
PKC ............................................................................................... Protein kinase C 
PLC .............................................................................................. Phospholipase C 
PPAR .................................................... Peroxisome proliferator-activated receptor 
PTX ......................................................................................................... Picrotoxin 
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PYY ....................................................................................................... Peptide YY 
Rin ................................................................................................... Input resistance 
RMP ........................................................................... Resting membrane potential 
S ................................................................................................................. seconds 
sEPSC........................................... spontanerous excitatory post-synaptic potential 
sIPSC .............................................. spontaneous inhibitory post-synaptic potential 
STZ .................................................................................................. Streptozotocin 
T1DM ................................................................................. Type I diabetes mellitus 
TEA ............................................................................................... Tetraethylamine 
TRH ........................................................................ Thyrotropin-releasing hormone 
TTX ..................................................................................................... Tetrodotoxin 
UCP .......................................................................................... Uncoupling protein 
VEH ............................................................................................................. Vehicle 
VSG ............................................................................ Vertical sleeve gastrectomy 
WAT ....................................................................................... White adipose tissue 
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Equipment Used 
List of equipment used for electrophysiology and brain slice preparation 
Vibrating Microtome ............................................................... Vibratome 1000 Plus 
Pipette Puller ......................................................................................... Sutter P-87 
Isolation Table ................................................................................................. TMC 
Microscope .................................................................................. Olympus BX51WI 
Digitizer ..................................................................................Axon Digidata 1440A 
Patch-Clamp Amplifier ......................................................... Axon Multiclamp 700B 
List of equipment used for immunohistochemistry and imaging 
Microscope ...................................................................................... Olympus BX41 
Camera ............................................................................................ Spot RT Slider 
Cryostat ........................................................................................Microm HM505 E 
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Patch-clamp rig diagram 
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Patch Clamp Frequency Response Calculator and Circuit Diagram 
This is an infographic made to illustrate the effects of series resistance (Rs) 
and membrane capacitance (Cm) on the frequency response characteristics of 
patch clamp recordings. The resistance and capacitance of neurons are set up in 
such a way as to create a 1st order lowpass filter on recorded currents (also called 
an RC filter). Typical resistance and capacitance values are in Ohms (Ω) and 
Farads (F). However, Rs and Cm are usually measured in MΩ and pF so the 
infographic was designed with this in mind.  
(A) Graphical representation -3dB cutoff frequency (corner frequency) as a
function of the RC product (Rs*Cm = MΩ*pF).  (B) Frequency response from 10Hz 
– 20,000 Hz for various RC product values. (C) Formula for calculation of -3dB
cutoff frequency of an RC filter. General formula is given first. The shorthand
formula is for “quick and dirty” calculation of cutoff frequency but is still 99.5%
accurate. The final formula is the RC filter transfer function and is used to calculate
the curves in B. For this formula, Rs and Cm must be in MΩ and pF respectively.
(D) Circuit diagram for patch clamp recordings. The RC filter is created by Rs and
Cm. Rm is assumed to be so much larger than Rs that it can be ignored.
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